CONTENTS - BioMed Central

Transcription

CONTENTS
Open Access
Volume 7
Supplement 1
2010
Editor-in-chief
Kuan-Teh Jeang
16th International Symposium on HIV and
Emerging Infectious Diseases
Marseille, France
24-26 March 2010
http://www.retrovirology.com/supplements/7/S1
I1-I32 – Invited speaker presentations
O1-O16 – Oral presentations
P1-P192 – Poster presentations
Retrovirology (http://www.
retrovirology.com) is an open
access journal published by
BioMed Central Ltd. The journal
publishes stringently
peer-reviewed, high-impact
articles on basic retrovirus
research. Retrovirology
(ISSN 1742-4690) is
indexed/tracked/covered by
PubMed Central, MEDLINE,
Thomson Reuters (ISI), Biosis,
CAS, CABI, Embase and
Current Contents.
Contact BioMed Central
supplements@
biomedcentral.com
w w w. i s h e i d . c o m
16
th
HIV & Emerging Infectious Diseases
VIH & Maladies Infectieuses Emergentes
International Symposium
Symposium International
24 X 26
March/Mars
2010
Parc Chanot
Marseille, France
FINAL PROGRAMME
PROGRAMME FINAL
SUMMARY
SOMMAIRE
Committees / Comités...............................................................................p. 02
Welcome Address / Message de bienvenue..........................................p. 03
General Information / Informations générales.......................................p. 04
Parc Chanot map / Plan du Parc Chanot.............................................. p. 09
Programme at a glance / Synopsis........................................................ p. 12
Wednesday 24 March / Mercredi 24 mars......................................... p. 14
Thursday 25 March / Jeudi 25 mars.................................................... p. 18
Friday 26 March / Vendredi 26 mars.................................................... p. 22
Posters / Communications affichées...................................................... p. 28
Authors index / Liste des auteurs........................................................... p. 49
Industry satellite symposia / Symposia satellites de l’industrie.....
p. 59
Exhibition / Exposition................................................................................ p. 60
Sponsors / Partenaires............................................................................ p. 62
COMMITTEES / COMITÉS
2010 Chairman / Président
 Alain LAFEUILLADE (France)
2010 Steering Committee /
Comité d’organisation 2010







Jean-François DELFRAISSY (France)
Jose GATELL (Spain)
Guido POLI (Italy)
Christine ROUZIOUX (France)
Vicente SORIANO (Spain)
Hans-J. STELLBRINK (Germany)
Stefano VELLA (Italy)
2010 Scientific Committee /
Comité Scientifique 2010

















Antoine CHERET (France)
Patricia ENEL (France)
Robert GALLO (USA)
Gilles HITTINGER (France)
Leondios KOSTRIKIS (Cyprus)
John KALDOR (Australia)
Denis LACOSTE (France)
Mark NELSON (UK)
Cecile POGGI (France)
Isabelle POIZOT-MARTIN (France)
Alain RIEU (France)
Paolo RIZZARDI (Italy)
Jurgen ROCKSTROH (Germany)
Caroline SOLAS (France)
Catherine TAMALET (France)
Giuseppe TAMBUSSI (Italy)
Jean-Claude TARDY (France)
2
WELCOME ADDRESS
MESSAGE DE BIENVENUE
Welcome to the 16th ISHEID!
I have the pleasure to welcome you to this new edition of the “International Symposium on HIV &
Emerging Infectious Diseases”, held for the first time in Marseille.
As you are aware, over the last 15 years, this event grew from a local meeting to an internationally
renowned congress. It is henceforth the stage welcoming the most distinguished experts, allowing
fruitful exchanges, and addressing the most exciting topics in the fields of HIV, hepatitis viruses
and emerging pathogens.
The ISHEID principles are primarily driven by Science and by the need to offer a better clinical
care to our patients. This is why the Steering Committee and the Scientific Committee are keen to
offer a cutting edge program in all sessions, including the satellite symposia. I would like to thank
particularly all the members of these Committees who helped me building this captivating program,
and all the speakers who agreed to be part of it. I also thank all the participants for the increased
number of abstracts submitted this year. This led to tough selection choices for oral presentations,
but also to a high quality in the poster sessions.
This year, the new location of Marseille allows better accommodation and accessibility than in the
past: we hope that you will appreciate this choice and keep some extra time to discover this charming
city.
Kindest regards;
Alain Lafeuillade, MD, On behalf of the Steering Committee
Bienvenue au 16ème ISHEID !
Au nom du Comité d’Organisation, j’ai le plaisir de vous accueillir à cette édition du « Symposium
International sur le VIH et les Maladies Infectieuses Emergentes » qui se tient pour la première fois
à Marseille.
Ce congrès a évolué sur les 15 dernières années d’une manifestation régionale à un rassemblement
scientifique de renommée internationale. Il est la scène sur laquelle vous rencontrez les experts les
plus avertis, où les sujets les plus « brûlants » sont traités, dans les domaines du VIH, des hépatites
virales, et des infections émergentes. Sa dimension permet au congrès d’assurer des échanges
fructueux directs entre participants et experts.
Les préoccupations essentielles de l’ISHEID sont scientifiques, ainsi que le besoin d’apporter à
nos patients une meilleure prise en charge. C’est pourquoi nous avons veillé à la haute tenue du
programme au sein de toutes les sessions, y compris les symposia satellites. Je tiens à ce propos à
remercier les membres des Comités d’Organisation et Scientifique qui m’ont aidé à construire un
programme riche et captivant, et l’ensemble des orateurs qui ont accepté d’y intervenir. Je remercie
également les participants pour avoir soumis un nombre accru de résumés cette année, avec une
qualité toujours croissante. Cela a eu, paradoxalement, l’effet de conduire à des choix difficiles dans
la sélection finale.
Cette année, la ville de Marseille permet aussi une meilleure accessibilité et un choix plus complet
d’hôtels. J’espère que vous saurez apprécier cette nouvelle destination et lui consacrerez aussi un peu
de temps.
En vous souhaitant un bon congrès ;
Dr Alain Lafeuillade, au nom du Comité d’Organisation
3
GENERAL INFORMATION
INFORMATIONS GENERALES
DATES & LOCATION/DATES ET LIEU
BADGE
A name badge will be provided on-site with
your registration documents. The wearing
of this badge is compulsory both inside the
conference rooms and in the exhibition area.
Un badge nominatif vous sera remis sur place
accompagné de vos documents de congrès.
Le port du badge est obligatoire dans
l’ensemble des salles de conférences et à la
zone d’exposition.
Colour code / Code couleur
Delegates / Participants white / blanc
The 16th ISHEID congress will be held from
Wednesday 24 March to Friday 26 March
2010 and will take place at:
Le 16ème congrès ISHEID se tiendra du
mercredi 24 mars au vendredi 26 mars 2010
au :
Speakers / Orateurs
turquoise
Exhibitors / Exposants
purple / violet
Organisation
red / rouge
PARC CHANOT DE MARSEILLE
BP 2 - 13266 Marseille Cedex 08
www.parc-chanot.com
IMPORTANT: Always keep your badge after
ISHEID. You will need to remove your certificate
functions of CME credits.
IMPORTANT : pensez à conserver votre badge
à l’issue d’ISHEID. Il vous sera indispensable
pour retirer votre attestation d’attributions de
points CME.
ACCESS TO THE PARC CHANOT /
ACCÈS AU PARC CHANOT
CELLULAR PHONES /
TÉLÉPHONES PORTABLES
Thank you for not using your cell phone in
conference rooms.
Nous vous remercions de ne pas utiliser
votre téléphone portable dans les salles de
conférence.
By metro / En métro
From Saint Charles station:
13 minutes.
Direction: Sainte Marguerite.
Exit station « Rond Point du Prado ».
More information: www.rtm.fr
A partir de la Gare Saint Charles :
13 minutes.
Direction : Sainte Marguerite.
Sortie station « Rond Point du Prado ».
Pour plus d’information : www.rtm.fr
Taxi from station / Taxi gare
Tel : +33 (0)4 91 02 20
CERTIFICATES OF ATTENDANCE /
CERTIFICATS DE PRÉSENCE
Certificates of attendance will be issued
to pre-registered delegates during the
withdrawal of their badge.
Registered delegates on site will receive this
certificate upon registration.
Les certificats de présence seront remis à
chaque participant pré-inscrit lors du retrait
de leur badge.
Les participants inscrits sur place se verront
remettre ce certificat lors de leur inscription.
CLOAKROOM / VESTIAIRE
A free cloakroom is at participant’s disposal
during the welcome desk opening hours. It is
located on level 2, hall des pas perdus.
Please make sure that no personal belongings
are left after closing each day.
Un vestiaire gratuit est à la disposition des
participants pendant les heures d’ouverture
de l’accueil. Il est situé au niveau 2, hall des
pas perdus.
4
Veuillez vous assurer qu’aucun effet personnel
n’est laissé après la clôture de chaque jour.
CME CREDITS / CRÉDITS CME
The 16th International Symposium on HIV and
Emerging Infectious Diseases is accredited
by the European Accreditation Council for
Continuing Medical Education
(EACCME) to provide the following CME activity
for medical specialists. The EACCME is an
institution of the European Union of Medical
Specialists (UEMS): www.uems.net.
The 16th International Symposium on HIV and
Emerging Infectious Diseases is designated
for a maximum of (or for up to) 18 hours of
European external CME credits. Each medical
specialist should claim only those hours of credit
that he/she actually spent in the educational
activity. The EACCME credit system is based
on 1 ECMEC per hour with a maximum of 3
ECMECs for half a day and 6 ECMECs for a
full-day event.
EACCME credits are recognized by the
American Medical Association towards the
Physician’s Recognition Award (PRA). To
convert EACCME credit to AMA PRA category
1 credit, contact the AMA: www.accme.org.
Le 16ème ISHEID est accrédité par l‘EACCME
(European Accreditation Council for Continuing
Medical Education) concernant les activités
de CME (Continuing Medical Education) pour
les médecins spécialistes. L‘EACCME est
une institution de l’UEMS (European Union of
Medical Specialists) : www.uems.net.
Le 16ème ISHEID est prévu pour un maximum
de 18 heures de crédits CME externes
européens. Les médecins spécialistes ne
peuvent se prévaloir que des heures qu’ils
ont effectivement passées dans une activité
éducative.
Le système de crédits CME est basé sur 1
crédit CME par heure avec un maximum de
3 crédits CME pour une demi-journée et 6
crédits pour une journée entière.
Les crédits EACCME sont reconnus par
l’AMA (American Medical Association towards
the Physician’s Recognition Award). Afin de
convertir un crédit EACCME en AMAPRA
catégorie 1, prière de contacter l’AMA :
www.accme.org.
The certificates will be issued the week
following the conference via the website:
www.isheid.com
Access will be using your last name, first name
and number on your badge (think of keeping it
after the conference).
Les attestations seront délivrées la semaine
suivant le congrès via le site Internet :
www.isheid.com
L’accès se fera à l’aide de votre nom, prénom
et du numéro figurant sur votre badge (penser
à garder celui-ci après le congrès).
5
COFFEE BREAKS / PAUSES CAFÉS
Coffee breaks will take place in the exhibition
area with the support of Gilead.
Les pauses-cafés auront lieu sur la zone
d’exposition avec le soutien de Gilead.
CONGRESS SECRETARIAT /
SECRÉTARIAT DU CONGRÈS
During the meeting / Durant le congrès
PARC CHANOT
Information and registration desks:
Level 2, Hall des pas perdus
Information et bureau des inscriptions :
Niveau 2, Hall des pas perdus
OPENING HOURS /
HEURES D’OUVERTURE
Wednesday 24 March / Mercredi 24 mars :
08:00 - 19:30
Thursday 25 March / Jeudi 25 mars :
07:30 - 18:30
Friday 26 March / Vendredi 26 mars :
07:30 - 17:00
After the meeting / Après le congrès
ISHEID 2010 c/o Colloquium
12 rue de la Croix-Faubin
75 557 Paris Cedex 11
Tel: + 33 (0)1 44 64 15 15
Fax: + 33 (0)1 44 64 15 16
E-mail: [email protected]
CURRENCY / MONNAIE
The national currency in France is the EURO
(1 Euro= 100 Cents). Coins of 1, 2 and 5 Cents
are copper-coloured; coins of 10, 20 and 50
Cents are gold-coloured; 1 and 2 Euro coins
are gold-and-silver coloured. Euro notes come
in denominations of 5, 10, 20, 50, 100, 200
and 500. Credit cards as well as most major
currencies are widely accepted. For currency
exchange, please ask your hotel for further
information.
La monnaie nationale en France est l’EURO
(1 euro = 100 cents). Les pièces de 1, 2 et
5 Centimes sont cuivrées ; les pièces de 10,
20 et 50 Centimes sont dorées ; les pièces
de 1 et 2 Euro sont dorées et argentées. Les
billets en Euro comportent des coupures de 5,
10, 20, 50, 100, 200 et 500. Les cartes de
crédit de même que la plupart des monnaies
principales sont largement acceptées. Pour
changer de l’argent, merci de vous adresser
à votre hôtel.
GENERAL INFORMATION
A cyber-space is located in the exhibition area,
next to the Tibotec booth. Computers stations
will be at your disposal for your internet
connections.
Un cyber-espace est situé dans la zone
d’exposition à côté du stand Tibotec. Des
ordinateurs sont à votre disposition pour vos
connexions internet.
Headsets will be distributed at the entrance of
the Congress Hall, in exchange for the voucher
which is in your delegate pack.
La langue officielle du congrès est l’anglais
excepté les sessions où un drapeau français
apparaît sur le programme.
Les casques de traductions sont distribués à
l’accueil en échange de votre bon d’échange
qui est dans votre dossier congressiste.
ELECTRICITY / ELECTRICITÉ
LOST AND FOUND / OBJETS TROUVÉS
CYBER-SPACE / CYBER-ESPACE
Lost items should be returned to the Congress
Information desk (level 2, hall des pas perdus)
which is at your disposal in case of loss of
items.
Les objets trouvés doivent être retournés à
la banque d’information de l’accueil (Niveau
2, hall des pas perdus) qui se tient à votre
disposition en cas de perte d’objet.
The electrical supply in most areas of France
is 220 V, 50 Hz. Plug sockets are European
continental standard (two round pins).
La charge électrique dans la plupart des
régions de France est 220 V, 50 Hz. Les
prises électriques sont au standard européen
continental (prise ronde bipolaire).
EXHIBITION / EXPOSITION
POSTERS /
COMMUNICATIONS AFFICHÉES
Located at Level 2, the exhibition is open
every day of the conference. It allows you to
develop and enrich your communication with
our partners and discover their products.
Située au niveau 2, l’exposition est ouverte
tous les jours du congrès. Elle vous permet de
développer et enrichir vos échanges avec nos
partenaires et de découvrir leurs produits.
OPENING HOURS /
HORAIRES D’OUVERTURES
Wednesday 24 March / Mercredi 24 mars :
08:00 - 19:30
Thursday 25 March / Jeudi 25 mars :
07:30 - 18:30
Friday 26 March / Vendredi 26 mars :
07:30 - 17:00
Posters are located in the Goudes Room,
level 2 / Les communications affichées sont
situées dans la salle les Goudes, niveau 2.
Opening hours / Horaires d’ouvertures :
Wednesday 24 March/Mercredi 24 mars:
09:00-19:30
Thursday 25 March/Jeudi 25 mars:
07:30-18:30
Friday 26 March/Vendredi 26 mars:
07:30-15:30.
The best poster will be awarded on Friday,
March 26 at 10:30 at the end of the plenary
session in the Auditorium.
Le prix du meilleur poster sera remis le vendredi
26 mars à 10h30 à la fin de la plénière dans
l’Auditorium.
INSURANCE POLICY /
ASSURANCE ET RESPONSABILITÉ
PROGRAMME CHANGES /
CHANGEMENTS DANS LE PROGRAMME
The Symposium Organiser can not accept
liability for personal injury, loss of or damage to
belongings of Symposium participants, either
during or as a result of the Symposium. Please
check the validity of your own insurance.
L’organisateur du Symposium ne peut être
rendu responsable en cas de dommages
aux personnes, de pertes ou de dommages
aux effets des participants du Symposium, ni
pendant, ni après celui-ci. Merci de vérifier la
validité de votre propre assurance.
The organisers cannot assume liability for any
changes in the programme due to external or
unforeseen circumstances.
Les
organisateurs
n’assument
aucune
responsabilité
pour
des
changements
dans le programme qui seraient dus à des
circonstances extérieures ou imprévisibles.
PUBLICATION OF ABSTRACTS /
PUBLICATION DES ABSTRACTS
All accepted abstracts are published on the
CD-Rom that will be given at Gilead booth
number 7 upon presentation of the voucher
included in the congress bag.
All accepted abstracts will be published also
after the congress in "Retrovirology":
http://retrovirology.com
LANGUAGE / LANGUES
The official congress language is English except
for sessions where a French flag appears on
the programme.
6
Les résumés acceptés sont publiés sur le
CD-Rom qui vous sera remis sur le stand
de Gilead, numéro 7, sur presentation du
voucher situé dans la sacoche. Les résumés
acceptés seront également publiés après le
congrès dans « Retrovirology » :
http://retrovirology.com
SMOKING POLICY / TABAC
It is forbidden to smoke anywhere in the Parc
Chanot.
Il est interdit de fumer dans l’ensemble des
espaces du Parc Chanot.
SPEAKER PREVIEW ROOM /
SALLE DES ORATEURS
The speaker preview room is located in the
Morgiou Room, level 2 at the Parc Chanot.
La salle des orateurs est située dans la salle
Morgiou, niveau 2 du Parc Chanot.
Speakers please proceed to the preview room
• At last 1 hour before the session for
MORNING presentations
• Between 9:00 am and 12:00 am on the day
of the session for AFTERNOON presentations.
Les orateurs sont pries de se rendre en salle
de pré-projection
• Au moins une heure avant la session pour les
présentations du matin
• Entre 9 :00 et 12 :00 le jour de la session
pour les présentations de l’après-midi.
USEFUL WEB SITES / SITES UTILES
ISHEID 2010:
www.isheid.com
Venue / Centre de conférence :
www.parc-chanot.com
Tourism / Office de tourisme :
www.marseille-tourisme.com
National airline company /
Compagnie aérienne nationale :
www.airfrance.fr
National train network / Réseau ferré national :
www.sncf.fr
Metro, bus in Marseille /Métro, bus dans
Marseille :
www.rtm.fr
7
WELCOME RECEPTION /
COCKTAIL DE BIENVENUE
The Welcome Reception on
March 2010 will take place
19:30 in the exhibition area.
Le cocktail de bienvenue aura
24 mars 2010 de 18:30
l’exposition.
Wednesday 24
from 18:30 to
lieu le mercredi
à 19:30 dans
GENERAL INFORMATION
CONGRESS REGISTRATION & CANCELLATION CONDITIONS /
INSCRIPTIONS CONGRÈS ET CONDITIONS D’ANNULATIONS
All rates are in Euros, French VAT 19,6%
included/ Tous les tarifs sont exprimés en
euros TTC.
REGISTRATION FEES INCLUDE / LES
DROITS D’INSCRIPTION INCLUENT :
Name Badge / Badge nominatif
Admission to all congress sessions,
poster area and exhibition area from
Wednesday 24 March to Friday 26
March / la participation aux sessions du
congrès, aux présentations posters et à la
zone d’exposition du mercredi 24 mars au
vendredi 26 mars.
Invitation to the welcome reception /
Invitation au cocktail de bienvenue
Congress documents (congress bag, final
programme, Abstracts CD-Rom, writing
pads and pens) / les documents du
congrès (sacoches, programme final, CDRom des abstracts, blocs-notes et stylos)
Coffee breaks from Wednesday 24 March
to Friday 26 March / les pauses café du
mercredi 24 mars au vendredi 26 mars.
Please note that no funds are available for
scholarships / Aucune bourse ou subvention
ne sera accordée.
Inscriptions sur place/Registration on site
Participant
460€
Reduced rate* / Tarif réduit*
110€
Reduced rate applicable to the following
categories:
AIDS Association Member
Students / Residents (please present a
copy of your student card).
Low and Middle income countries
(World Bank List
http://go.worldbank.org/K2CKM78CC0)
Nurses
Le tarif réduit est applicable aux catégories
suivantes :
Membres d’associations de lutte contre le
SIDA
Etudiants et internes (Sur envoi d’un
justificatif : photocopie de la carte
d’étudiant pour l’année en cours)
Pays à faible et moyen revenus
(World Bank List
http://go.worldbank.org/K2CKM78CC0)
Infirmier(e)s
CANCELLATION POLICY FOR INDIVIDUAL REGISTRATIONS /
CONDITIONS D’ANNULATION INSCRIPTIONS INDIVIDUELLES
All cancellations must be notified in writing to: / Toutes annulations doivent être notifiées par écrit
à:
ISHEID 2010 c/o Colloquium
12 rue de la Croix-Faubin
75 011 Paris, France
Fax : + 33 1 44 64 15 16
E-mail : [email protected]
AFTER JANUARY, 15: NO REFUND. With no payment received before that date, the total
amount will still remain due to the Congress office. / En l’absence de paiement reçu avant cette
date, le montant total restera dû au secrétariat du Congrès.
APRÈS LE 15 JANVIER : AUCUN REMBOURSEMENT All refunds will be issued after the
congress. Requests will not be accepted after the 30 April 2010. / Tous les remboursements
seront effectués après le congrès et aucune demande ne sera traitée après le 30 avril 2010.
ACCOMMODATION/ HÉBERGEMENT
WIP is the official hotel reservation centre in charge of accommodation for the 2010 ISHEID
Congress.
WIP est la centrale de réservation hôtelière officielle pour la gestion de l’hébergement du congrès
ISHEID 2010.
For any information please contact / Pour toute information, veuillez contacter :
Marie Cohade
Tel : 33 1 70 36 04 25 - E-mail : [email protected]
8
9
EXHIBITION AREA / ZONE D’EXPOSITION
ENTRANCE / ENTRÉE
CLOAKROOM / VESTIAIRE
MORGIOU ROOM / SALLE MORGIOU
PREVIEW
WELCOME AREA/ ZONE D’ACCUEIL
AMPHITHEATER CALLELONGUE / AMPHITHÉÂTRE CALLELONGUE
AUDITORIUM
GOUDES ROOM / SALLE LES GOUDES
POSTERS
PARC CHANOT MAP
PLAN DU PARC CHANOT
GENERALNOTES
INFORMATION
10
11
PROGRAMME AT A GLANCE
SYNOPSIS
WEDNESDAY 24 MARCH 2010
9:30
Auditorium
11:00
Amphitheater Callelongue
Plenary Session
11:30
Coffee break sponsored by Gilead
Parallel Sessions
13:00
Parallel Sessions
Long Term HIV Management (I)
Pharmacology of HIV
Industry Satellite Symposium
Session COREVIH
Schering Plough
Shapping the Future of HIV-HCV
Co-infected Patients
In French only
14:00
Plenary Session
15:30
16:00
Immunology of HIV
Keynote Lecture
17:00
by Robert GALLO
25 Years after Discovering HIV as the
Cause of AIDS: Prospects for a Vaccine
MSD
Steering for New Strategies
18:30
THURSDAY 25 MARCH 2010
8:30
Auditorium
Plenary Session
10:30
11:00
12:30
HIV Reservoirs & Primary Infection
Parallel Sessions
Parallel Sessions
HIV Resistance
Free Oral Presentations (I)
Tibotec Janssen-Cilag
Switching from Stable Regimen:
Which Risks, Which Benefi ts?
14:00
Plenary Session
15:30
16:00
Antiretroviral Strategies
Keynote Lecture
by Albert OSTERHAUS
17:00
The Global Challenge of
Abbot Virology
HIV, a Chronic Disease:
what Priorities to manage?
18:30
FRIDAY 26 MARCH 2010
8:30
Auditorium
Plenary Session
10:30
11:00
12:30
Co-Infections
Parallel Sessions
Parallel Sessions
HIV Controllers
Free Oral Presentations (II)
Parallel Sessions
14:00
15:00
15:30
16:30
Long Term HIV Management (II)
with the support of Bristol Myers Squibb
Parallel Sessions
Discussed Posters
Parallel Sessions
Parallel Sessions
Towards an HIV Vaccine
Post-CROI
Reporter Session
12
MERCREDI 24 MARS 2010
9:30
Auditorium
Amphithéâtre Callelongue
Session Plénière
11:00
11:30
13:00
Maladies Infectieuses Émergentes
Pause - café sponsorisée par Gilead
Sessions Parallèles
Gestion à Long Terme de l’Infection à VIH (I)
VIH, Session Pharmacologique
Symposium Satellite de l’Industrie
Session COREVIH
Schering Plough
Modeler l’Avenir des Patients
Co-infectés VIH-VHC
En français seulement
14:00
Session Plénière
15:30
16:00
Immunologie du VIH
Conférence Plénière
17:00
par Robert GALLO
25 Ans après avoir découvert le VIH comme
Agent Causal du SIDA : Recherche d’un Vaccin
MSD
Mettre le Cap
sur de Nouvelles Stratégies
18:30
JEUDI 25 MARS 2010
8:30
Auditorium
Session Plénière
10:30
11:00
12:30
Réservoirs du VIH & Primo-infection
Résistances du VIH
Présentations Orales Libres (I)
Tibotec Janssen-Cilag
Changement de Traitement Antirétroviral
chez les Patients en Succès Virologique :
Quels Risques, Quels Bénéfices ?
14:00
Session Plénière
15:30
16:00
Stratégies Antirétrovirales
Conférence Plénière
par Albert OSTERHAUS
17:00
Le Défi Mondial des Maladies Émergentes
Abbot Virology
Le VIH, une Pathologie Chronique :
Quelles Priorités à prendre en charge ?
18:30
VENDREDI 26 MARS 2010
8:30
Auditorium
Session Plénière
10:30
11:00
Co-Infections
12:30
Patients VIH « Non Progresseurs »
Présentations Orales Libres (II)
14:00
Gestion à Long Terme de l’Infection à VIH (II)
avec le Support de Bristol Myers Squibb
15:00
Mise au point d’un Vaccin contre le VIH
« Post-CROI »
15:30
16:30
Posters Discutés
L’ essentiel du Symposium
13
WEDNESDAY 24 MARCH
MERCREDI 24 MARS
9:20  9:30
Welcoming Message / Message de Bienvenue
On Behalf of the Steering Commitee / Au nom du Comité d’Organisation
Alain Lafeuillade, Toulon, France
9:30  11:00
Plenary session / Session plénière
EMERGING INFECTIOUS DISEASES /
MALADIES INFECTIEUSES EMERGENTES
Auditorium
Chairpersons: Pierre Dellamonica (Nice, France), Gilles Hittinger (Toulon, France)
 9:30
I-01 Hepatitis E: State-of-the-Art / Hépatite E : Etat des Lieux
Harry Dalton, Royal Cornwall Hospital & Virus Reference Department, London, UK
 10:00
I-02 Lessons Learned from Chikungunya / Chikungunya : Leçons et Perspectives
Giovanni Rezza, Istituto Superiore di Sanità, Rome, Italy
 10:30
I-03 The Influenza Challenge / Le Défi Grippal
Tim Nguyen, World Health Organisation (WHO), Geneva
11:00  11:30
Coffee break sponsored by /
Pause café sponsorisée par
11:30  13:00
Parallel session / Sessions parallèles
LONG-TERM HIV MANAGEMENT (I) /
GESTION A LONG TERME DE L’INFECTION A VIH (I)
Auditorium
Chairpersons: Isabelle Poizot-Martin (Marseille, France), Hervé Tissot-Dupont (Marseille, France)
 11:30
I-04 Ageing with HIV: Next Challenges / Vieillir avec le VIH : Défis à Venir
Martin Fisher, Brighton and Sussex University Hospital, NHS, Brighton, UK
 12:00
I-05 Cardiovascular Disease and HIV / Risque Cardiovasculaire et VIH
Esteban Martinez, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain
 12:15
I-06 Ageing Metabolism and HIV / Vieillissement Métabolique et VIH
Jacqueline Capeau, INSERM, Paris, France
 12:35
I-07 Neurodegeneration in the HAART Era / Dégénérescence Neurologique à l’Epoque des
Trithérapies
Bruce Brew, University of New South Wales, Sydney, Australia
Traduction simultanéé FR/AN and AN/FR
Simultaneous translation FR/EN and EN/FR
14
WEDNESDAY 24 MARCH / MERCREDI 24 MARS
PHARMACOLOGY OF HIV /
VIH, SESSION PHARMACOLOGIQUE
Amphitheater Callelongue / Amphithéâtre Callelongue
Chairpersons: Rodolfe Garraffo (Nice, France), Caroline Solas (Marseille, France)
 11:30
I-08 Diffusion of New Antiretroviral Drugs in CSF / Diffusion des Nouveaux anti-Rétroviraux dans le LCR
Francesca Aweeka, University of California San Francisco, San Francisco, USA
 11:50
I-09 Inhibitory Quotient in HIV Pharmacology / Le Quotient Inhibiteur en Pharmacologie VIH
Charles La Porte, Ottawa Health Research Institute, Ottawa, Canada
 12:10
I-10 Drug-Drug Interactions - It is not only CYP450’s which Matter / Interactions
Pharmacologiques en dehors du Cytochrome P450
David Back, University of Liverpool, Liverpool, UK
 12:30
I-11 Evidence-based TDM for Antiretroviral Drugs / Le Suivi Pharmacologique des ARV Fondé
sur les Preuves
Caroline Solas, Hôpital de la Timone, Marseille, France
13:00  14:00
Industry Satellite Symposium /
SCHERING PLOUGH
SHAPPING THE FUTURE OF HIV-HCV CO-INFECTED PATIENTS /
MODELER L’AVENIR DES PATIENTS CO-INFECTES VIH-VHC
Chairperson: Stanislas Pol (Paris, France)
 13:00
Characteristics and Care of HIV-HCV Coinfected Patients (Prospecth study 2009) / Profil et
Prise en Charge des Patients Co-Infectés VIH-VHC en 2009 (Etude Prospecth 2009)
Patrice Cacoub, Service de Médecine Interne, CHU Pitié Salpétrière, Paris, France
 13:15
Maximizing Chances of Cure for HIV-HCV Coinfected Patients / Optimiser les Chances de
Guérison chez les Patients Co-infectés VIH-VHC
Stéphanie Dominguez, Service d’Immunologie Clinique, Hôpital Henri Mondor, Paris, France
 13:30
Protease Inhibitor: Efficacy and Mutations Management / Anti-Protéases : Efficacité et
Gestion des Résistances
Christian Payan, Département de Microbiologie, CHU – Hôpital Morvan, Brest, France
 13:45
Protease Inhibitor: a Trial in HIV-HCV Coinfecetd Patients / Anti-Protéases : un Protocole
chez les Patients Co-infectés VIH-VHC
Stanislas Pol, Unité d’Hépatologie, Hôpital Cochin, Paris, France
 13:50
Questions - Answers / Questions – Réponses
15
WEDNESDAY 24 MARCH
MERCREDI 24 MARS
13:00  14:00
Session COREVIH
Session in French only / Session en français uniquement
LE DEPISTAGE COMMUNAUTAIRE
Auditorium
Modérateurs : Isabelle Ravaux (Marseille, France), Chantal Vernay-Vaïsse (Marseille, France)
 13:00
Introduction sur le COREVIH
Isabelle Ravaux, PH en infectiologie, AP-HM, vice-présidente du Corevih Paca Ouest Corse
 13:05
Introduction sur le Dépistage Rapide
Chantal Vernay-Vaïsse, chef de service Prévention IST, Conseil Général des Bouches du Rhône
 13:10
Dépistage Rapide Auprès des Gays : le projet ANRS «DRAG»
Bruno Spire, chercheur en sociologie, Inserm U 912, président de AIDES, Marseille, France
 13:25
Aspects Sociaux du Dépistage ou Expériences Européennes
Jean-Yves Le Talec, chercheur en sociologie, Université de Toulouse - Le Mirail, Toulouse, France
 13:40
Discussion avec la salle
14:00  15:30
IMMUNOLOGY OF HIV / IMMUNOLOGIE DU VIH
Auditorium
Chairpersons: Giuseppe Tambussi (Milan, Italy), Jean-François Delfraissy (Paris, France)
 14:00
I-12 Is there a Role for Cytokine-Immune Based Therapy in HIV Disease Therapy? /
Les Traitements Immunologique avec des Cytokine ont-ils une Place dans le VIH ?
Guido Poli, Istituto San Raffaele, Milan, Italy
 14:30
I-13 IL-2/IL-7 Therapies in HIV Infection. From CD4 Increases to Clinical Outcomes /
Immunothérapie de l’infection par le VIH par IL-2 et IL-7
Yves Lévy, Hôpital Henri Mondor, Créteil, France
 15:00
I-14 NK Cells and Immune Activation in HIV / Cellules NK et Activation Immune dans l’Infection
à VIH
Martin R. Goodier, Imperial College London, London, UK
15:30  16:00
16
WEDNESDAY 24 MARCH / MERCREDI 24 MARS
16:00  17:00
Keynote lecture / Conférence plénière
Auditorium
KL-1 25 Years after Discovering HIV as the Cause of AIDS: Prospects for a Vaccine / 25 Ans
Après Avoir Découvert le VIH Comme Agent Causal du SIDA : Recherche d’un Vaccin
Robert Gallo, University of Maryland School of Medicine, Institute of Human Virology, Baltimore, USA
17:00  18-30
MSD
Symposium in French only / Symposium en français uniquement
STEERING FOR NEW STRATEGIES /
METTRE LE CAP SUR DE NOUVELLES STRATÉGIES
Chairpersons: Alain Lafeuillade (Toulon, France), Jacques Izopet (Toulouse, France)
 Can we Expect more than Undetectable Viremia Today? / Peut-on Attendre Plus que
l’Indétectabilité Virologique Aujourd’hui
Constance Delaugerre, Service de Virologie, CHU Saint Louis, Paris, France
 New Pharmacological Needs: Diffusion Outside the Blood Compartment? /
Nouvelles Exigences Pharmacologiques : Diffusion Extra-Plasmatique ?
Rodolphe Garraffo, Hôpital Pasteur, Nice, France
 First Line HAART: a Decisive Choice for the Long-Term / Première Ligne de Traitement :
un Choix Décisif pour le Long Terme
Isabelle Poizot Martin, HIV-Clinical center, Hospital Sainte Marguerite, Marseille, France
17
THURSDAY 25 MARCH
JEUDI 25 MARS
8:30  10:30
HIV RESERVOIRS & PRIMARY INFECTION /
RESERVOIRS DU VIH ET PRIMO-INFECTION
Auditorium
Chairpersons: Jacques Izopet (Toulouse, France), Alain Lafeuillade (Toulon, France)
 8:30
I-15 HIV Latency Explained to Clinicians / La Latence du VIH expliquée aux Cliniciens
Jose Alcami, Instituto de Salud Carlos III, Madrid, Spain
 9:00
I-16 Update on HIV Reservoirs / Actualités sur les Réservoirs du VIH
Sarah Palmer, Swedish Institute for Infectious Disease Control and Karolinska Institute, Stockholm, Sweden
 9:30
I-17 Anti-HIV Latency Drugs / Traitements Anti-Latence
David Margolis, University of North Carolina, Chapel Hill, USA
 10:00
I-18 Translational Research at Acute HIV Infection / Recherche Translationnelle au Stade
de Primo-infection
Jean-Pierre Routy, McGill University, Montreal, Canada
10:30  11:00
11:00  12:30
Parallel sessions / Sessions parallèles
HIV RESISTANCE / RESISTANCE DU VIH
Auditorium
Chairpersons: Catherine Tamalet (Marseille, France), Jean-Claude Tardy (Lyon, France)
 11:00
I-19 Use of New Technologies to Detect and Understand HIV Drug Resistance / Utilisation
de Nouvelles Technologies pour Détecter et Comprendre les Résistances du VIH
Michael Kozal, Yale University, New Haven, USA
 11:30
I-20 Resistance to New Antiretrovirals (ETV, Anti-Integrases, Entry Inhibitors) / Résistance
aux Nouveaux Anti-rétroviraux (Etravirine, anti-Intégrase, anti-CCR5)
Francesca Ceccherini-Silberstein, University of Rome Tor Vergata, Rome, Italy
 12:00
I-21 Use of New Drug Resistance Markers to Predict Virologic Response to Antiretrovirals
/ Utilisation de Nouveaux Marqueurs de Résistance pour Prédire la Réponse Virologique aux
Anti-rétroviraux
Mark Wainberg, McGill University, Montreal, Canada
18
THURSDAY 25 MARCH / JEUDI 25 MARS
11:00  12:30
FREE ORAL PRESENTATIONS I / PRESENTATIONS ORALES LIBRES I
Chairpersons: Patricia Enel (Marseille, France), Philippe Halfon (Marseille, France)
* indicates the presenting author / * indique le présentateur
 11:00
O-01 Evolution of Tuberculosis/HIV Co-Infection in California During the Haart Era, 1996-2007
John Metcalfe (1)* Matt Facer (2) Mark Damesyn (2) Qiang Xia (2) James Watt (3) Julia Hill (3) Philip
Hopewell (1) Janice Westenhouse (3) Jennifer Flood (3)
(1) UCSF, San Francisco, USA (2) Office of AIDS, California Department of Public Health, San Francisco,
USA (3) TB Control Unit, California Department of Public Health, Richmond, USA
O-02 CANCELLED
 11:10
O-03 Screening of Differentially Expression Gene in HIV/HCV Coinfection Patients.
zhengrong Yang (1)* Jing Zhao (1) Lin Chen (1)
(1) Shenzhen Center for Disease Control and Prevention, Shenzhen, China
11:20
O-04 Nk-pDC Cross-Talk Leads to the Generation of Mtrail+Ifn-Α+Cytotoxic pDC s Following
HIV-1 Infection of pDC s. Consequences on the Control of Viral Replication
Héla Saïdi (1) Marlene Bras (1)* Formaglio Pauline (1) Melki Marie-thérèse (1) Gougeon Marie-Lise (1)
(1) Institut Pasteur, Paris, France
 11:30
O-05 Th1/Th17 Gammadelta T Cells Are Expanded in HIV-1 Infected Patients and Respond
to Candida Albicans.
Alessandro Poggi (1)* Daniela Fenoglio (2) Florinda Battaglia (2) Silvia Catellani (3) Alessandra Musso (1, 6)
Maurizio Setti (4) Giuseppe Murdaca (5) Maria Raffaella Zocchi (6)
(1) National Institute for Cancer Research, Genoa, Italy (2) CEBR, University of Genoa, Genoa, Italy (3)
Department of Oncohematology, University of Genoa, Genoa, Italy (4) Department of Internal Medicine,
University of Genoa, Genoa, Italy (5) Department of Semiotics, University of Genoa, Genoa, Italy (6) Scientific
Institute San Raffaele, Department of Immunology, Milan, Italy
 11:40
O-06 NK-Dependent Survival of HIV-1 Infected DCs. Pivotal Role of HMGB1.
Marie-Thérèse Melki (1)* Héla Saïdi (1) Marie-Lise Gougeon (1)
(1) Institut Pasteur, Paris, France
 11:50
O-07 γδ T Cells are ADCC Effectors in Elite HIV Controllers
Bhawna Poonia (1) David Riedel (1) Cristiana Cairo (1) Mohammed Sajadi (1) Cheryl Armstrong (1) David
Pauza (1)*
(1) Institute of Human Virology, University of Maryland Medical School, Baltimore, USA
 12:00
O-08 CpG Methylation Controls Reactivation of HIV from Latency
Jana Blazkova (1, 2, 3)* Katerina Trejbalova (1, 2) Francoise Gondois-Rey (1) Halfon Philippe (4) Philibert
Patrick (5) Eric Verdin (6) Daniel Olive (1) Carine van Lint (3) Jiri Hejnar (2) Ivan Hirsch (1)
(1) INSERM, UMR891, Centre de Recherche en Cancérologie de Marseille and Institut Paoli-Calmettes, and
Université Méditerranée, Marseille, France (2) Institute of Molecular Genetics, Academy of Sciences of the
Czech Republic, Prague, Czech Republic (3) Laboratory of Molecular Virology, Institute for Molecular Biology
and Medicine (IBMM) University of Brussels (ULB), Gosselies, Belgium (4) Department of Virology, Alphabio
Laboratory, Marseille, France (5) Department of Infectious Diseases, Hôpital Ambroise Paré, Marseille,
France (6) Gladstone Institute of Virology and Immunology, San Francisco, USA
19
THURSDAY 25 MARCH
JEUDI 25 MARS
12:30  14:00
UNE DIVISION DE
TIBOTEC JANSSEN CILAG
Symposium in English only / Symposium en anglais uniquement
SWITCHING FROM STABLE REGIMEN: WHICH RISKS, WHICH BENEFITS? /
CHANGEMENT DE TRAITEMENT ANTIRÉTROVIRAL CHEZ LES PATIENTS
EN SUCCÈS VIROLOGIQUE : QUELS RISQUES, QUELS BÉNÉFICES ?
Chairpersons: Isabelle Poizot-Martin (Hôpital Sainte Marguerite, Marseille, France), Jose
Arribas (Hospital La Paz, Madrid, Spain)
 NNRTI regimen: Capitalizing on the class? / Associations avec un INNTI : changer en
capitalisant sur la classe ?
Mark Nelson, Chelsea and Westminster Hospital, London, UK
 PI/r regimen: Without compromising the high genetic barrier? / Associations avec IP/r :
changer sans compromettre la barrière génétique à la résistance ?
Gianni di Perri, Department of Infectious Diseases, University of Torino, Torino, Italy
 From 3 to 1: Is monotherapy a valid option for simplification? / De 3 vers 1 : la
monothérapie est elle une option ?
Christine Katlama, Service de Maladies Infectieuses et Tropicales, CHU Pitié Salpétrière, Paris, France
14:00  15:30
ANTIRETROVIRAL STRATEGIES / STRATEGIES ANTIRETROVIRALES
Auditorium
Chairpersons: Hans J Stellbrink (Hamburg, Germany), Alain Rieu (Toulon, France)
 14:00
ARV Strategies in 2010: What’s New? / Stratégies de Traitement : Quoi de Neuf en
2010 ?
Jose Gatell, University of Barcelona, Barcelona, Spain
 14:30
ARV Therapy in Special Populations / Traitement Antirétroviral dans des Populations
Particulières
Stéfano Vella, Istituto Superiore di Sanità, Rome, Italy
 15:00
Novel Targets, Novel Strategies / Nouvelles Cibles, Nouvelles Stratégies
Robert Redfield, Institute of Human Virology, Baltimore, USA
15:30  16:00
20
THURSDAY 25 MARCH / JEUDI 25 MARS
16:00  17:00
Keynote lecture / Conférence plénière
Auditorium
The Global Challenge of Emerging Infectious Diseases / Le Défi Mondial des
Maladies Emergentes
Albert Osterhaus, Head Department of Virology, Erasmus MC, Rotterdam, The Netherlands
17:00  18-30
ABBOTT
HIV, A CHRONIC DISEASE: WHAT PRIORITIES TO MANAGE? /
LE VIH, UNE PATHOLOGIE CHRONIQUE : QUELLES PRIORITÉS
À PRENDRE EN CHARGE ?
Chairpersons: Alain Lafeuillade (Toulon, France), Christine Katlama (Paris, France)
 HIV, Antiretrovirals and Central Nervous System / VIH, Antirétroviraux et Système
Nerveux Central
Scott Letendre, Division of Infectious Diseases, University of California San Diego, San Diego, USA
 Management of Metabolic Disorders / La Gestion des Troubles Métaboliques
Jean-Luc Meynard, Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, Paris, France
 HIV Eradication, An Achievable Goal? / L’éradication, Un Objectif Atteignable ?
Jean-Claude Tardy, Hôpital de la Croix Rousse, Lyon, France
21
FRIDAY 26 MARCH
VENDREDI 26 MARS
8:30  10:30
CO INFECTIONS / CO-INFECTIONS
Auditorium
Chairpersons: Marc Bourlière (Marseille, France), Isabelle Ravaux (Marseille, France)
 8:30
I-22 HIV / HPV Coinfection: State-of-the-Art / Co-infection VIH et HPV : Actualités
Franco Buonaguro, Laboratory of Molecular Biology and Viral Oncogenesis & AIDS Reference Center,
Naples, Italy
 9:00
I-23 Hepatitis B: Treatment Strategies and Resistance / Hépatite B : Stratégies
Thérapeutiques et Résistance
Vicente Soriano, Hospital Carlos III, Madrid, Spain
 9:30
I-24 New anti-HCV Drugs in the Pipeline / Les Nouvelles Molécules anti-VHC
Marc Bourlière, Fondation Saint Joseph, Marseille, France
 10:00
I-25 Liver Transplantation in Co-infected Patients / Transplantation Hépatique chez les
Patients Co-infectés
Jose M Miró, Hospital Clínic, Barcelona, Spain
BEST POSTER AWARD / REMISE PRIX POSTER
Courtesy of / Courtoisie de ViiVhealthcare
10:30  11:00
11:00  12:30
HIV CONTROLLERS / PATIENTS VIH « NON PROGRESSEURS »
Auditorium
Chairpersons: Antoine Cheret (Toulon, France), Olivier Lambotte (Le Kremlin-Bicêtre, France)
 11:00
I-26 HIV Controllers: State-of-the-Art / Non Progresseurs : Etat des Lieux
Olivier Lambotte, INSERM U802, Université Paris-Sud, Le Kremlin-Bicêtre, France
 11:30
I-27 The Role of Cytotoxic T Cells / Rôle des Cellules T Cytotoxiques
Asier Sáez-Cirión, Unité de Régulation des Infections Rétrovirales, Institut Pasteur, Paris, France
 11:50
I-28 Potential Inflammatory Consequences in HIV Controllers / Conséquences Possibles de
l’Inflammation chez les Non Progresseurs
Peter Hunt, Positive Health Program, San Francisco General Hospital, San Francisco, USA
 12:10
The Role of Host Genetic Determinants / Rôle des Facteurs Génétiques
Paul de Bakker, Brigham and Women’s Hospital, Harvard Medical School-Partners Healthcare Systems
Center for Genetics and Genomics, Boston, USA
22
FRIDAY 26 MARCH / VENDREDI 26 MARS
11:00  12:30
FREE ORAL PRESENTATIONS II / PRESENTATIONS ORALES LIBRES II
Chairpersons: Eric Jullian (Toulon, France), Patrick Phillibert (Marseille, France)
 11:00
O-09 Morbidity Associated with Hepatitis E Virus Infection in Endemic Setting.
Michael Favorov (1)* Makhmud Sharapov (2)
(1) International Vaccine Institute, Seoul, Korea, Republic of (2) Tashkent Pediatric Medical Institute and
Central Asia Epidemiology Network, Ministry of Health, Tashkent, Uzbekistan
 11:10
O-10 Hepatic Cytolysis and Hepatitis E Virus Infection in HIV-Positive Patients.
Marie-Christine Mazeron (1) Elisabeth Nicand (2) Sophie Tesse (2) Esma Badsi (3) Jean-Dominique Magnier
(3) Marie-José Sanson Le Pors (1) Jean-François Bergmann (3) Pierre Sellier (3)*
(1) Hôpital Lariboisière, Service de bactériologie-Virologie, Paris, France (2) Hôpital d’Instruction des
Armées du Val de Grace, CNR virus de l’hépatite E, Paris, France (3) Hôpital Lariboisière, service de
Médecine Interne, Paris, France
 11:20
O-11 Co-Receptor Usage Prediction at Quasispecies Level Using Ultra-Deep Pyrosequencing
on both Circulating and Proviral HIV in Patients Candidates to CCR5 Antagonist Treatment
Isabella Abbate (1)* Gabriella Rozera (1) Chiara Tommasi (1) Alessandro Bruselles (1) Barbara Bartolini (1)
Emanuele Nicastri (1) Pasquale Narciso (1) Maria R. Capobianchi (1)
(1) INMI L.Spallanzani, Rome, Italy
 11:30
O-12 Semen May Harbor HIV Despite Effective HAART : Another Piece in the Puzzle
Philippe Halfon (1)* Claude Giorgetti (2) Hacène Khiri (1) Guillaume Pénaranda (1)* Terriou (2) G PorcuBuisson (2) Véronique Chabert-Orsini (2)
(1) Laboratoire Alphabio, Marseille, France (2) Institut Médical de Reproduction, Marseille, France
 11:40
O-13 Tenofovir (TDF) Containing First-Line HAART is Associated with Changes in Plasma
Parameters Suggestive of Increased Bone Resorption
Pablo Labarga (1)* Pablo Barreio (1) Carlos A. Sanchez (1) Jose Medrano (1) Eugenia Vispo (1) Jose
Vicente Fernandez (1) Francisco Blanco (1) Juan Gonzalez-Lahoz (1) Vicente Soriano (1)
(1) Hospital Carlos III, Madrid, Spain
 11:50
O-14 Side Effects Associated with Use of Nevirapine in HIV Treatment Naïve Patients with
Respect to Baseline CD4 Count
Manoj Shevkani (1)* Bankim Mankad (1) Goral Rathod (1) Bipin Amin (1) Asha Shah (1) Umesh Nihalani (1)
Hemang Purohit (1) Burzin Kavina (1) Urvi Derasari (1) Sanjeev Prajapati (1)
(1) ART center B J Medical College, Ahmedabad, India
 12:00
O-15 The Monet Trial: Correlation Between Hepatitis C Coinfection and HIV RNA Responses
During Darunavir/Ritonavir Monotherapy, for Patients With HIV RNA <50 Copies/mL at
Baseline.
Jose Arribas (1)* Maria Luisa Montes (1) Andrew Hill (2) Manyu Prakash (2) Christiane Moecklinghoff (2)
MONET Study Group (3)
(1) Hospital la Paz, Madrid, Spain (2) Tibotec, Mechelen, Belgium (3) MONET Study Group, Europe, Spain
 12:10
O-16 Inhibitors of Human Immunodeficiency Virus-1 Replication Targeting the Human DeadBox Polypeptide 3 (DDX3) RNA Helicase
Giovanni Maga (1)* Federico Falchi (2) Anna Garbelli (1) Marco Radi (2) Stefania Paolucci (3) Fausto
Baldanti (3) Maurizio Botta (2)
(1) Institute of Molecular Genetics IGM-CNR, Pavia, Italy (2) Dept. of Technical Pharmacology, University of
Siena, Siena, Italy (3) Virology Unit, University Hospital IRCCS S.Matteo, Pavia, Italy
23
FRIDAY 26 MARCH
VENDREDI 26 MARS
12:30  14:00
Paralllel sessions / Sessions parallèles
LONG-TERM HIV MANAGEMENT (II) /
GESTION A LONG TERME DE L’INFECTION A VIH (II)
Auditorium
Chairpersons: Isabelle Poizot Martin (Marseille, France), Pierre Cau (Marseille, France)
With the support of Bristol-Myers Squibb / avec le soutien de Bristol-Myers Squibb
 12:30
I-29 Progeria: a model for HIV? / La Progéria : un Modèle pour le VIH ?
Pierre Cau, Université de la Méditerranée Aix-Marseille II, Marseille, France
 12:50
I-30 Accelerated Immune Senesence in HIV / Vieillissement Immunologique Accéléré dans
l’Infection VIH
Victor Appay, Hôpital Pitié-Sâlpétrière, Paris, France
 13:10
I-31 Bone Aging and HIV / Vieillissement Osseux et VIH
Patrick Mallon, University College Dublin, Dublin, Ireland
 13:20
Sexual Dysfunction: HIV, HAART or premature aging? / Troubles Sexuels : VIH, traitement,
ou vieillissement accéléré ?
Giovanni Guaraldi, University of Modena and Reggio Emilia, Modena, Italy
12:30  14:00
DISCUSSED POSTERS / COMMUNICATIONS AFFICHEES DISCUTEES
Chairpersons: Mark Wainberg (Montreal, Canada), Jade Ghosn (Paris, France), Antoine Cheret
(Toulon, France)
 12:30
P-001 HIV/AIDS Infection in Ukraine: A Review of Epidemiological Data
Dr. Larissa Burruano (1)*
(1) CompNet, Clinic for Dermatology and Allergology, Ruhr-University, Bochum, Germany
 12:35
P-002 Human Papillomavirus(HPV) Genotypes Among HIV-Infected and HIV-Uninfected
Women in Mozambique
Massimo Magnano San Lio (1, 2)* Ivo Marchetti (3) Carla Carrilho (4) Maria Pia Cioni (3) Giovanni Guidotti
(3, 1) Cristina Moscatelli (3, 1) Fabio Taponeco (6) Elias Suizane F. Walle (5) Ines Zimba (7) Generoso
Bevilacqua (3)
(1) Community of Sant’Egidio, Drug Resources Enhancement against AIDS and Malnutrition (DREAM)
Program, Roma, Italy (2) Azienda U.S.L. Roma F, Civitavecchia, Italy (3) Division of Surgical, Molecular and
Ultrastructural Pathology, University of Pisa and University Hospital of Pisa, Pisa, Italy (4) Department of
Pathology, Universidade Eduardo Mondlane, Hospital Central de Maputo, Ministério de Saúde, Maputo,
Mozambique (5) Department of Gynecology, Hospital Central de Maputo, Ministério de Saúde, Maputo,
Mozambique (6) Department of Gynecology,University Hospital of Pisa, Pisa, Italy (7) DREAM Health Center
of Benfica, Maputo, Mozambique
 12:40
P-003 Factors Affecting Human Immunodeficiency Virus/ Acquired Immune Deficiency
Syndrome Preventive Behavior among Pregnant Women in ANC Clinic in Maternity Hospital,
Nepal
Sumi Amatya (1)*
(1) London School of Hygiene and Tropical Medicine, London, UK
24
 12:45
P-004 Treatment of Highly Pathogenic Filovirus Infections using Advanced Antisense
Technology
Travis Warren (1)* Kelly Warfield (1, 3) Jay Wells (1) Dana Swenson (1, 3) Candace Lovejoy (2, 4) Patrick
Iversen (2) Sina Bavari (1)
(1) USAMRIID, Ft. Detrick, Maryland, USA (2) AVI BioPharma, Inc., Corvallis, Oregon, USA (3) Integrated
BioTherapeutics, Inc., Germantown, Maryland, USA (4) Siga Technologies, Inc., Corvallis, Oregon, USA
 12:50
P-005 The HIV-1 Viral Protein TAT Modulates Glutamate and GABA Exocytosis from Human
and Mouse Neocortical Nerve Endings by Acting at Different Binding Sites
Maria Summa (1) Paolo Severi (1) Aldamaria Puliti (1) Maurizio Raiteri (1) Anna Pittaluga (1)*
(1) DIMES, Genova, Italy
 12:55
P-006 A Role for the Tetraspanin CD81 on the Late Steps of HIV-1 Replication in
T-Lymphoblastic Cells
Delphine Muriaux (1)*
(1) Inserm U758, LYON, France
 13:00
P-007 Highjacking Of PI3K/AKT Signaling Pathway by Hepatitis C Virus in TLR9-Activated
Human Plasmacytoid Dendritic Cells
Jonathan Florentin (1)* Clélia Dental (1) Guylène Firaguay (1) Françoise Gondois-Rey (1) Vassili Soumelis (2)
Thomas F. Baumert (3) Jacques A. Nunès (1) Daniel Olive (1) Ivan Hirsch (1)
(1) INSERM, UMR891, Centre de Recherche en Cancérologie de Marseille and Institut Paoli-Calmettes,
and Université Méditerranée, Marseille, France (2) Institut Curie, Paris, France (3) INSERM UMR_S748,
Université de Strasbourg, Strasbourg, France
 13:05
P-008 Multicolor Flow Cytometry Analysis of Innate Responses Following in Vitro Interaction
of PBMC with Hepatitis C Virus
Françoise Gondois-Rey (1)* Diana Herrera (1) Daniel Olive (1) Ivan Hirsch (1)
(1) INSERM, UMR891, Centre de Recherche en Cancérologie de Marseille and Institut Paoli-Calmettes, and
Université Méditerranée, Marseille, France
 13:10
P-009 Comparison Of Cytotoxic Activity and Interferon-G Secretion by Natural Killer Cells in
HIV-1 and HIV-2 Infected Individuals.
Samuel Victor Nuvor (1)* Sarah Rowland-jones (2) Hilton Whittle (3) Assan Jaye (3)
(1) University of Cape Coast, Cape Coast, Ghana (2) wetherall Institute of Molecular Medicine, Oxford, UK
(3) Medical Research Council, Banjul, Gambia
 13:15
P-010 Late HIV Infection Modulates the Expression and Activity of Cathepsin B, and its
Inhibitors in Macrophages: Implications in Neuropathogenesis.
Eillen Rodriguez (1)* Marines Plaud (1) Rafael Romeu (2) Richard Skolasky (3) Loyda Melendez (1)
(1) University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico (2) University of Puerto
Rico: Main Campus, San Juan , Puerto Rico (3) John Jopkins University, Baltimore, Maryland, USA
 13:20
P-011 Impact of Short Term HAART Initiated during the Acute or Chronic Stage on SIV
Infection of the Male Genital Tract
Marina Moreau (1)* Anna Le Tortorec (1) Hélène Denis (1) Claire Deleage (1) Anne-Pascale Satie (1) Olivier
Bourry (1) Pierre Roques (2) Bernard Jégou (1) Roger Le Grand (2) Nathalie Dejucq-Rainsford (1)
(1) Inserm U625 GERHM, Rennes, France (2) Service d’immuno-virologie, CEA, Fontenay-aux-roses, France
 13:25
P-012 Enhanced Induction of HIV-Specific CTL by Dendritic Cell-Targeted Delivery of SOCS-1
siRNA
Sandesh Subramanya (1, 2)* Chunting Ye (1, 2) Sang-Soo Kim (1, 2) Premalata Shankar (1, 2)
(1) TTUHSC, El Paso, USA (2) Harvard Medical School, Boston, USA
25
FRIDAY 26 MARCH
VENDREDI 26 MARS
 13:30
P-013 Effect of Antiretroviral Therapy (ART) on HIV-1 & 2 (Subtype C) Infection and its
Relationships to Cognitive Function and Quality of Life.
Gopukumar Kumarpillai (1)* Shobini L. Rao (1, 2) Prabha S.Chandra (1, 2) Satishchandra* (1, 2)
Mahendra Kumar (1, 2, 3)
(1) University of Calgary, Calgary, Canada (2) NIMHANS, Bangalore, India (3) Miami School of Medicine,
Florida, USA
P-014 CANCELLED
 13:35
P-015 Effect of Range of Spread of CD4 Count and RNA Level on the Efficacy of HIV
Treatments
George Towfic (1)* Samira Kettoola (1)
(1) Clarke College, Dubuque, USA
 13:40
P-016 HIV Infection in Elderly Patients Aged more than 65 Years
Farahnaz Almasi (1)*
(1) Paris 6 University, Paris, France
14:00  15:00
TOWARDS AN HIV VACCINE / MISE AU POINT D’UN VACCIN CONTRE LE VIH
Auditorium
Chairpersons: Alain Lafeuillade (Toulon, France), Pierre Pellegrino (London, UK)
 14:00
Mucosal Immunity : a New Pathway for HIV Vaccine Development / L’Immunité Muqueuse :
une Nouvelle Voie pour la Mise au Point de Vaccins
Marc Girard, Académie Nationale de Médecine, Lyon, France
 14:15
I-32 Recent Insights from Basic Science / Données Récentes des Sciences Fondamentales
Patrice Debré, INSERM U945, C.E.R.V.I., Paris, France
 14:30
I-33 Progress Towards Development of an HIV Vaccine: A Report from the AIDS Vaccine
Conference / Progrès vers la Mise au Point d’un Vaccin anti-VIH
Luigi Buonaguro, Molecular Biology and Viral Oncogenesis Unit & AIDS Reference Center, Istituto Nazionale
Tumori «Fond. G. Pascale», Naples, Italy
 14:45
What Can we Expect? / Que Peut-on Attendre ?
Giuseppe Pantaleo, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
26
14:00  15:00
POST CROI SESSION / SESSION « POST-CROI »
Chairpersons: Gérard Lepeu (Avignon, France), Jade Ghosn (Paris, France)
This session is dedicated to sum up the recent data presented at the 17th Conference on
Retroviruses and Opportunistic Infection (CROI) held in San Francisco, USA on February 16-20, 2010.
/ Cette session a pour but de résumer les faits marquants de la dernière CROI organisée à San
Francisco, USA, du 16 au 20 Février 2010.
 14:00
in Epidemiology / en Epidémiologie
Sabine Yerly, Hôpitaux Universitaires de Genève, Geneva, Switzerland
 14:15
in Virology / en Virologie
Leondios Kostrikis, University of Cyprus, Nicosia, Cyprus
 14:30
in Immunology / en Immunologie
Marie-Lise Gougeon, Institut Pasteur, Paris, France
 14:45
in Therapy / en Thérapeutique
Jade Ghosn, CHU Bicêtre, Paris, France
15:00  15:30
15:30  16:30
Reporter Session / L’Essentiel du Symposium
Auditorium
Chairpersons: Catherine Tamalet (Marseille, France), Alain Lafeuillade (Toulon, France)
 15:30
Virological Aspects / Aspects Virologiques
Jean-Claude Tardy, Hôpital de la Croix Rousse, Lyon, France
 15:45
Immunological Aspects / Aspects Immunologiques
Guido Poli, Istituto San Raffaele, Milan, Italy
 16:00
Clinical Aspects of HIV & Other Infections / Aspects Cliniques
Hans J Stellbrink, Infektionsmedizinisches Centrum Hamburg ICH, Hamburg, Germany
 16:15
Therapeutic Aspects of HIV & Other Infections / Aspects Thérapeutiques
Mark Nelson, Chelsea and Westminster Hospital, London, UK
27
POSTERS
Goudes Room / Salle Les Goudes
Posters are located in the Goudes room, level 2.
The best poster will be awarded on Friday, March 26 at 10:30 at the end
of the plenary session in the Auditorium.
Les communications affichées sont situées dans la salle Les Goudes,
niveau 2.
Le prix du meilleur poster sera remis le vendredi 26 mars à 10h30 à la
fin de la plénière dans l’Auditorium.
POSTERS MAP /
PLAN DES COMMUNICATIONS AFFICHEES
Discussed posters
COFFEE
BREAK
PAUSE
CAFE
Basic Sciences
A
Clinical Sciences
B
Epidemiology
& Prevention
C
Pharmacology
D
Emerging Infectious
Diseases
E
28
Discuted posters
P001 - P016
A: Basic Sciences
A1: HIV, Virology
P017 - P021
A2: HIV, Immunology
P022 - P027
A3: Hepatitis, Virology
P028 - P029
A4: Hepatitis, Immunology
P030 - P031
B: Clinical Sciences
B1: HIV, Clinical Manifestations
P033 - P041
B2: HIV, Therapy
P042 - P061
B3: HIV, Side Effects
P062 - P069
B4: HIV, Tumors
P070 - P071
B5: HIV, Others
P072 - P082
B6: Hepatitis, Therapy
P083 - P084
Total B7: Hepatitis, Other
P085 - P087
B8: STDs
P088
B9: Other, Clinical Science
P090 - P094
C: Epidemiology & Prevention
C1: HIV, Epidemiology & Prevention
P095 - P149
C2: Hepatitis, Epidemiology & Prevention
P150 - P154
C3: Other, Epidemiology & Prevention
P155 - P162
D: Pharmacology
D1: HIV, New Drugs
P163 - P166
D3: Therapeutic Drug Monitoring
P167
E: Emerging Infectious Diseases
E1: Laboratory Aspects
P168 - P175
E2: Clinical Aspects
P176 - P180
E4: Other, Emerging Infectious Diseases
P181 - P192
29
POSTERS
* indicates the presenting author /* indique le présentateur
A Basic Science
 A1: HIV, Virology
P-017 Pro 2000, a Broadly Active Anti-HIV Sulfonated Compound, Inhibits Viral Entry by
Multiple Mechanisms.
Dana Huskens (1) Albert T Profy (2) Kurt Vermeire (1) Dominique Schols (1)*
(1) Rega Institute for Medical Research, Leuven, Belgium (2) Indevus Pharmaceuticals, Lexington,
USA
P-018 Potential Role of HIV-1 NEF and Human M6B in HIV-Associated Neurological
Disorders
Jessica Moetter (1)* Silke Hoffmann (1) Esther Jonas (2) Dieter Willbold (1, 2)
(1) Forschungszentrum Juelich, ISB-3, Structural Biochemistry, Juelich, Germany (2) HeinrichHeine-Universitaet Duesseldorf, Institut fuer Physikalische Biologie, Duesseldorf, Germany
P-019 CANCELLED
P-020 HIV-1 Evolution and Drug Resistance among Patients Receiving Antiretroviral Therapy
in San Mateo County, California, 1997-2006.
Sudeb Dalai (1)* Jonathan Dyal (1) Keyan Salari (1) Seble Kassaye (1) Vivian Levy (2) Dennis
Israelski (2) David Katzenstein (1)
(1) Stanford University School of Medicine, Stanford, USA (2) San Mateo Medical Center, San
Mateo, USA
P-021 Length Variation in HIV-1 GP120 as the Product of DNA Misalignment Mechanism
Silvia Guglietta (1) Giuseppe Pantaleo (1) Cecilia Graziosi (1)*
(1) CHUV, Lausanne, Switzerland
 A2: HIV, Immunology
P-022 Nucleolin Relocalization Associated with Pre-Lethal Alterations of T Cell Morphology:
Redefining Cell Death in HIV Infection.
Giuseppa Visalli (1) Maria Paola Bertuccio (1) Cristina Chirico (1) Giovanni Pellicanò (3) Pasquale
Spataro (1) Riccardo Ientile (4) Isa Picerno (1) Giuseppe Piedimonte (2)*
(1) Department of Hygiene and Pubblic Health University of Messina, Messina, Italy (2) Department
of Biomorphology and Biotechnology University of Messina, Messina, Italy (3) Department of
Human Patology University of Messina, Messina, Italy (4) Department of Biochemistry University of
Messina, Messina, Italy
P-023 The Immunoglobulin Constant Region Modulates Antigen Binding Affinity and
Functional Activities of the Broadly Neutralizing 2F5 HIV Specific Antibody
Daniela Tudor (1)* Anne-Sophie Drillet (1) Isabelle Schwartz-Cornil (2) Ruizhong Shen (3) Phillip D.
Smith (3) Morgane Bomsel (1)
(1) Institut Cochin, Paris, France (2) INRA, Jouy-en-Josas, France (3) University of Birmingham,
Alabama, USA
P-024 Definition of the Interacting Interfaces of Apobec3G and HIV-1 Vif using Mappit
Mutagenesis Analysis
Delphine Lavens (1, 2)* Frank Peelman (1, 2) José Van der Heyden (1, 2) Isabel Uyttendaele (1, 2)
Dominiek Catteeuw (1, 2) Bertrand Van Schouwbroeck (3) Julia Kurth (3) Sabine Hallenberger (3)
Reginald Clayton (3) Jan Tavernier (1, 2)
(1) University of Ghent, Ghent, Belgium (2) VIB, Ghent, Belgium (3) TIBOTEC, Mechelen, Belgium
30
P-025 Expansion of Vdelta1 T Lymphocytes Reactive to C. Albicans in HIV-1 Infected
Patients: Effect of Influenza Virus Vaccine.
Maria Raffaella Zocchi (1)* Daniela Fenoglio (2) Alessia Parodi (2) Alessandra Ferrera (2) Paolo
Durando (3) Roberto Gasperini (3) Silvia Catellani (4) Alessandro Poggi (5)
(1) Scientific Institute San Raffaele, Department of Immunology, Milan, Italy (2) CEBR, University
of Genoa, Genoa, Italy (3) Department of Health Science, San Martino Hospital, Genoa, Italy (4)
Department of Oncohematology, Universiti of Genoa, Genoa, Italy (5) National Institute for Cancer
Research, Unit of Molecular Oncology and Angiogenesis, Genoa, Italy
P-026 HIV-Patients Discrimination According to Phenotype and Functional Assay of T-Cells
Subsets.
Marie-Paule Guillaume (1)* Rafik Karmali (1) Francis Corazza (1) Jean Duchateau (1)
(1) CHU-Brugmann, Bruxelles, Belgium
P-027 Evaluation of Adult Immunological Outcomes from Kimironko Health Center Art
Program, 2007 to 2008.
Andre Mbayiha H. (1)*
(1) AIDS Healthcare Foundation, Kigali, Rwanda
 A3: Hepatitis, Virology
P-028 Implications of HCV Natural Genetic Diversity on HCV NS5B Inhibitor NM283
Victoria L Demetriou (1)* Leondios G Kostrikis (1)
(1) University of Cyprus, Nicosia, Cyprus
P-029 Viral Variability Study in Follow-Up Sera from HIV-HBV-HCV Coinfected Patients
Stefania Taffon (1) Domenico Genovese (1, 2) Stefano Dettori (1) Paola Chionne (1) Claudio
Argentini (1, 2) Maria Blasi (1) Stefania Catone (1, 2) Nicoletta Marino (3) Francesco Mazzotta (3)
Maria Rapicetta (1)*
(1) Istituto Superiore di Sanita’, Dept. MIPI, Viral Hepatitis Uni, Rome, Italy (2) Istituto Superiore
di Sanita’, Dept. FARM, Rome, Italy (3) Santa Maria Annunziata Hospital, Infectious Diseases
Department, Florence, Italy
 A4: Hepatitis, Immunology
P-030 Pilot Trial of Oral Therapeutic HIV Vaccine, V-1 Immunitor, on HIV and HIV/HCV
Patients in Russia
aldar bourinbaiar (1)* vladimir orlovsky (1) vichai jirathitikal (1) orapun metadilogkul (1) popov dmitry
(1, 1)
(1) immunitor USA Inc, college park, USA
P-031 Evaluation of Immune Response Profiles of Individuals With Chronic Hepatitis C
Treated with Interferon Alpha and Ribavirin, in the Foundation of Tropical Medicine of
Amazonas.
Ana Ruth Araújo (2) Liziara Silva Fraporti (1, 3) Kátia Luz Torres (1) João Paulo Diniz Pimentel (1)
Tatiane Amabile (1) Andrea Tarragô (1) Laura Patrícia Viana Maia (1, 3) Nadja Garcia (1, 3) Walter
Luiz Neves (1) Adriana Malheiro (1, 3)*
(1) Fundação de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil (2) Fundação de
Medicina Tropical do Amazonas, Manaus, Brazil (3) Universidade do Amazonas, Manaus, Brazil
 A5: Others, Basic Science
P-032 CANCELLED
31
POSTERS
B Clinical Science
 B1: HIV, Clinical Manifestations
P-033 HIV-Related Morbidity Rate, Thirteen Years after the Introduction of Highly Active
Antiretroviral Therapy (1996-2009)
Roberto Manfredi (1)*
(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy
P-034 The «AIDS Presenters» Phenomenon, Thirteen Years after the Availability of Potent,
Combination Antiretroviral Therapy
P-035 The Prevalence and Presentation of Heart Disease in HIV Positive Adults Attending a
Clinic at Mulago Hospital, Kampala, Uganda
Andrew Ocero (1, 2)* Elly Katabira (2) Roy Mugerwa (2)
(1) Northern Uganda Malaria AIDS and Tuberculosis Programme, Gulu, Uganda (2) Makerere
University, Kampala, Uganda
P-036 A 16-Year Prospective Survey of Mycobacterium Xenopi, Mycobacterium Kansasii
and Mycobacterium Fortuitum Infection in Patients with HIV Disease
P-037 Vitamin D and HIV: Implications for Chronic Disease Management
Toby Dyner (1)* Virginia Cafaro (1) Valby Chow (1)
(1) SHARED PERSPECTIVES ON THERAPIES(SPOT), San Francisco, USA
P-038 Abstract Assessment of Knowledge, Attitude and Risk Practice for HIV Infection
among Male Prisoners: The Case Maweni Prison, Tanga Region Tanzania
Joan Karomba (1)*
(1) Muhimbili National Hosp, Dar es saalam, Tanzania, United Republic of
P-039 Clinical and Immunological Presentation of New HIV-Infected Patients in an
Outpatient Clinic
Edna Quintas (1) Sara Cardoso (1)* Carmela Pineiro (1) Danina Ferreira (1) Rosario Serrao (1)
Jorge Soares (1) Rui Marques (1) Antonio Sarmento (1)
(1) Infectious Diseases. Hospital Sao Joao, Porto, Portugal
P-040 An HIV-Infected Patient with Associated, Lethal Rhinopharyngeal Actinomycosis and a
Rapidly Progressing Local Adenocarcinoma
Roberto Manfredi (1)* Sergio Sabbatani (1) Ciro Fulgaro (1)
(1) Infectious Diseases, S. Orsola Hospital, Bologna, Italy
P-041 More than Ten Years without any Detectable HIV Viremia: Exceptionally Long-Term
Non-Progressive HIV Infection
Roberto Manfredi (1)* Sergio Sabbatani (1) Giovanni Fasulo (1) Ciro Fulgaro (1)
32
 B2: HIV, Therapy
P-042 Antiretroviral Treatment and Expression of the mRNA Levels for PGP, MRP1, MRP4
and MRP5 in HIV Antiretroviral Naïve Patients. Follow-Up at 48 Weeks.
Francesca Falasca (1) Francesca Graziano (1) Laura Antonelli (2) Paola Maida (1) Claudia Montagna
(1) Bambina Rizzo (1) Vincenzo Renda (2) Guido Antonelli (1) Ombretta Turriziani (1)*
(1) Department of Experimental Medicine, Virology Section, Sapienza University , Rome, Italy (2)
Department of Infectious Diseases Umberto I Hospital, Rome, Italy
P-043 Clinical and Immulogical Outcomes among Adult Patients Receiving Antiretroviral
Therapy (ART) at an HIV/AIDS Program in Uganda
Simon Muhumuza (1)* Julius Ssempiira (1) Fred Semitala (1) Jennifer Namusobya (1) Joseph
Ouma (1) Enid Mbabazi (1) Moses Kamya (1)
(1) Mulago-Mbarara Teaching Hospital’s Joint AIDS Program (MJAP), Kampala, Uganda
P-044 Recombinant Soluble CCR5 and CXCR4 Chemokine Receptors as Anti-HIV Drug
Targets
Victoria Kurbatska (1, 2)* Zhanna Rudevica (1, 2) Alexander Tsimanis (3) Ainars Leonciks (1, 2)
(1) Latvian Biomedical Research and Study center, Riga, Latvia(2) ASLA Biotech, Riga, Latvia(3)
Bioactivity Ltd., Rehovot, Israel
P-045 Two Recent, Fixed Associations of Antiretroviral Nucleos(T)Ide Analogues. A
Prospective Assessment of their Therapeutic use in HIV Disease Management. A
Field Study
P-046 Factors Associated with Non-Adherence to HAART in HIV-Positive Pregnant Women
During Pregnacy, Peri- and Postpartum in Lima, Peru
Romina Tejada (1)* Jorge Alarcón (1) Carlos Velásquez (2) César Gutiérrez (1)
(1) Instituto de Medicina Tropical, UNMSM, Lima, Peru(2) Instituto Nacional Materno Perinatal,
Lima, Peru
P-047 Treatment of HIV-2 Infection with Ritonavir/Lopinavir: Results at 60 Months. A
Single-Center Study of 9 Patients
Philippe Genet (1)* Tahar Touahri (1) Laurence Courdavault (1) Frédérique Plassart (1) Juliette
Gerbe (1)
(1) CH Victor Dupouy, Argenteuil, France
P-048 Efficacy and Tolerability of RAL, MVC and ETV Used in Combination in the Treatment
of Highly Treatment Experienced HIV Infected Patients
Shilpa Sayana (1) Homayoon Khanlou (1)*
(1) AIDS Healthcare Foundation, Los angeles, USA
P-049 Outcome of 1st Line Antiretroviral Therapy (ART) with Respect to Treatment Failure
at Art Centre, B. J. Medical College, Civil Hospital, Ahmedabad
Bipin Amin (1)* Urvi Derasari (1) Umesh Nihalani (1) Hemang Purohit (1) Manoj Shevkani (1)
Sanjeev Prajapati (1) Girish Prajapati (1) Bankim Mankad (1) Asha Shah (1) Burzin Kavina (1)
P-050 Analysis of Protease Treatment-Associated Mutations in a Group of HIV-1 Subtype F
Infected Individuals with Two Sequences Obtained in Different Time Points
Márcia Perez Resende Oliveros (1, 3)* Clarice Gameiro da Fonseca Pachi (2) Jorge Futoshi
Yamamoto (2) Elizabeth Cavalieri (3) Maria Cecilia Araripe Sucupira (3) Luis Fernandez Lopez (1, 4)
Ricardo Sobhie Diaz (3)
(1) School of Medicine, University of São Paulo – LIM 01 - HCFMUSP, Sao Paulo, Brazil (2)
ANSP- Academic Network of São Paulo, Sao Paulo, Brazil (3) Federal University of São Paulo –
Retrovirology Laboratory, Sao Paulo, Brazil (4) CIARA – (Center for Internet Augmented Research
and Assessment) – Florida International University, Miami, USA
33
POSTERS
P-051 Efficacy and Safety of TDF+FTC+EFV in Naïve Patients Initiating HAART; an
Observational Study Comparing Atripla vs Truvada/Sustiva Exposure.
Carlos Alberto Sanchez (1)* Jose Medrano (1) Pablo Labarga (1) Eugenia Vispo (1) Aida Calviño (1)
Luz Martín-Carbonero (1) Pablo Barreiro (1) Vicente Soriano (1)
(1) Hospital Carlos III, Madrid, Spain
P-052 Fusion Inhibitors and their Evolving Role During Salvage Antiretroviral Therapy. Seven
Years of Experience with Enfuvirtide
P-053 Our Experience in 2nd Line Anti Retroviral Therapy (ART) at State AIDS Clinical
Expert Panel (SACEP) Clinic, Centre of Excellence (CoE), Art Centre, B. J. Medical
College, Civil Hospital, Ahmedabad
Bankim Mankad (1)* Hemang Purohit (1) Asha Shah (1) Manoj Shevkani (1) Burzin Kavina (1) Bipin
Amin (1) Umesh Nihalani (1) Sanjeev Prajapati (1) Urvi Derasari (1) Girish Prajapati (1)
P-054 Treatment Outcomes in Patients Receiving Combination Antiretroviral Therapy
Kenneth Agu (1)* Uche Ochei (1) Azuka Oparah (1) Obialunamma Onoh (2)
(1) Department of Clinical Pharmacy and Pharmacy Practice, University of Benin, Benin, Nigeria (2)
West African Postgraduate College of Pharmacists, Lagos, Nigeria
P-055 Lopinavir/R + Efavirenz Combination as a Potent NRTI Sparing Antiretroviral
Therapy.
Philippe Henrivaux (1)* Yvette Fairon (2) Benoît Kabamba (3) Jean-Cyr Yombi (4) Patrick Goubau (3)
Bernard Vandercam (4)
(1) CHC Clinique St Joseph, Médecine Interne, Liège, Belgium (2) ASBL, Liège, Belgium (3)
Laboratoire de Référence SIDA, Cliniques Universitaires Saint Luc, Brussels, Belgium (4) Centre de
Référence SIDA, Cliniques Universitaires Saint Luc, Brussels, Belgium
P-056 Experience with Art Adherence Couselling at Muhimbili National Hospital,Dar Es
Salaam,Tanzania
Joan Karomba (1)*
(1) Muhimbili National Hosp, Dar Es Salaam, Tanzania, United Republic Of
P-057 Interventions to Promote Adherence to Antiretroviral Therapy (HAART) among Adult
Patients at an HIV/AIDS Program in Uganda:
Simon Muhumuza (1)* Violet Gwokyalya (1) Elizabeth Kutamba (1)
(1) Mulago-Mbarara Teaching Hospitals’ Joint AIDS Program (MJAP), Kampala, Uganda
P-058 Lowering HIV Fitness and Replication Rate by Administration of Lamivudine Alone,
in Extensively Resistant HIV-Infected Patients, as a «Bridging» Strategy Towards
Optimized Salvage Regimens
P-059 Impact of Maraviroc on Immune Restoration in an Advanced Stage HIV-Infected
Patient
Sylvie Bregigeon (1) Amélie Menard (1) Olivia Faucher (1) Catherine Tamalet (2) Caroline Solas (3)
Véronique Obry-Roguet (1) Isabelle Poizot-Martin (1)*
(1) Department of Immuno-hematology, HIV-Clinical center, Hospital SainteMarguerite, Marseilles,
France (2) Fédération de Microbiologie Clinique, Hôpital de la Timone, Marseilles, France (3)
Laboratoire de Pharmacocinétique et de Toxicologie, Hôpital de La Timone, Marseilles, France
P-060 «Self-Managed», Inadequate «Adherence» to Antiretroviral Therapy, Limited to one
Half of Standard Dosages, Followed by an Unexpected, Sustained Virological and
Immunological Success
34
P-061 Without a Quality Management Tool, All HIV Managers Shall not Realise any Steps
Forward for Improvement. A Taso Uganda Experience.
Denis Mpiima (1)* Ceasar Luzze (1) Nicholas Kizito (1, 1)
(1) The AIDS Suport Organisation, Kampala, Uganda
B3: HIV, Side Effects
P-062 Cystatin C and Cardiovascular Risk in HIV Infected Patients
Katia Falasca (1) Claudio Ucciferri (1)* Paola Mancino (1) Francesca Vignale (1) Jacopo Vecchiet
(1)
(1) Infectious Disease Clinic, Department of Medicine and Science of Aging, G. d’Annunzio
University, Chieti, Italy
P-063 Effects on Insulin Sensitivity and Hepatic Safety of Atazanavir in HCV/HIV Coinfected
Patients versus HIV Monoinfected. A Prostective 48-Week Study.
Héctor Meijide (1) Álvaro Mena (1)* Ángeles Castro (1, 2) Pilar Vázquez (1) Soledad López (1)
Joaquín Serrano (1) Laura Bello (1) José Pedreira (1)
(1) HIV Unit, Internal Medicine Service. Universitary Hospital of A Coruña, A Coruña, Spain (2)
University of A Coruña, A Coruña, Spain
P-064 Hypertension and Microalbuminuria in HIV Infected Patients: Beneficial Effects of the
Treatment with Telmisartan
Claudio Ucciferri (1)* Paola Mancino (1) Katia Falasca (1) Francesca Vignale (1) Jacopo Vecchiet
(1)
(1) Infectious Disease Clinic, Department of Medicine and Science of Aging, “G. d’Annunzio”
University , Chieti, Italy
P-065 NRTIS (ZDV and D4T) Side Effects in PLHAS Attending the Antiretroviral Treatment
Centre of B. J. Medical College and Civil Hospital at Ahmedabad, Gujarat, India
Umesh Nihalani (1)* Asha Shah (1) Burzin Kavina (1) Bipin Amin (1) Urvi Derasari (1) Hemang
Purohit (1) Bankim Mankad (1) Sanjeev Prajapati (1) Girish Prajapati (1) Manoj Shevkani (1)
P-066 Depression and Self-Esteem of Patients Positive for HIV / AIDS in an Inland City of
Brazil
Carolina Castrighini (1) Elucir Gir (1)* Lis Neves (1) Renata Reis (2) Marli Galvão (3) Myeko
Hayashido (1)
(1) São Paulo University - School Of Nursing Ribeirão Preto, Ribeirão Preto, Brazil (2) Alagoas
Federal University , Maceió, Brazil (3) Ceará Federal University, Fortaleza, Brazil
P-067 A Young Patient with Perinatal HIV Infection Treated for 17 Consecutive Years with
Antiretroviral Therapy: Extremely Severe Lipo-Accumulation Picture
P-068 Emerging HIV-Associated Concerns: Osteopenia and Osteoporosis. Easy Prevention
and Management Guidelines
P-069 Interactive Theatre for HIV/AIDS Side Effects on Youth Sexuality Reproductive Health
and Rights in Pakistan to Learn and Practice
Sana Sohail (1)*
(1) Chanan Development Association (CDA), Lahore, Pakistan
35
POSTERS
 B4: HIV, Tumors
P-070 Interplay Between HIV and Micrornas in AIDS-Related Lymphomas
Giulia De Falco (1)* Anna Luzzi (1) Federica Morettini (1) Anna Onnis (1) Lorenzo Leoncini (1)
(1) Dept. Human Pathology & Oncology, University of Siena, Siena, Italy
P-071 Non-AIDS Related Malignancies 13 Years after the Availability of Combined
Antiretroviral Therapy
 B5: HIV, Others
P-072 Prolonged Elevation of Viral Loads in HIV-1-Infected Children in a Region of Intense
Malaria Transmission in Northern Uganda
Herbert Kiyingi (1, 2)* Thomas Egwang (1) Maria Nannyonga (2)
(1) medbiotech Laboratories, Kampala, Uganda (2) Nsambya Hospital, Kampala, Uganda
P-073 Women HIV Education, Capacity Building and Economic Empowerment Initiative
Caroline Agochukwu (1)*
(1) Health Matters Incorporated, Lagos, Nigeria
P-074 Tuberculosis with Pulmonary Involvement in HIV Patients
Lígia Fernandes (1)* Nuno Marques (2) Ana Lebre (2) Joaquim Oliveira (2) José Saraiva da Cunha
(2) António Meliço Silvestre (2)
(1) Serviço de Pneumologia, Centro Hospitalar de Coimbra, Coimbra, Portugal (2) Departamento de
Doenças Infecciosas, Hospitais da Universidade de Coimbra, Coimbra, Portugal
P-075 Service Outcome of Antiretroviral Post-Exposure Prophylaxis (PEP) for Occupational
HIV Exposure among Health Care Personnel
Asha Shah (1)* burzin kavina (1) sanjeev prajapati (1) hemang purohit (1) manoj shevkani (1) urvi
derasari (1) umesh nihalani (1) bipin amin (1) bankim mankad (1) girish Prajapati (1)
P-076 Glomerular Filtration (GF) Determined by Creatinine Clearance (CCR) in 24 Hours
Urine and Cockcroft & Gault (CG) and Modification of Diet in Renal Disease (MDRD)
Equations in a Large Cohort of HIV+ Patients
Pablo Labarga (1)* Marta Albalate (2) Pablo Barreiro (1) Elena Alvarez (1) Luz Martín-Carbonero
(1) Javier Pinilla (3) Eugenia Vispo (1) Jose Medrano (1) Carlos A Sanchez (1) Vicente Soriano (1)
(1) Hospital Carlos III, Madrid, Spain (2) Hospital Infanta Leonor, Madrid, Spain (3) Hospital San
Pedro, Logroño, Spain
P-077 Factors Associated with Development of Opportunistic Infections among Patients on
Art at a Ugandan Program-MJAP
Simon Muhumuza (1)* Joseph Ouma (1) Fred Semitala (1)
(1) Mulago-Mbarara Teaching Hospitals Joint AIDS Program (MJAP), Kampala, Uganda
P-078 Evaluation of the Therapeutic Educational Consultations of Patients Infected by the
Human Immunodeficiency Virus (HIV)
Jennifer Grangé (1) Frederique Plassart (1)*
(1) Charles Foix Hospital, Ivry sur seine, France
P-079 CANCELLED
36
P-080 Immune Response Characterization in HIV/HCV Co-Infected Patients of Medicine
Tropical Foundation
Adriana Malheiro (1, 3)* Liziara Silva Fraporti (1, 3) Flamir Victoria (2) Kátia Luz Torres (1) João
Paulo Diniz Pimentel (1) Andrea Tarragô (1) Laura Patricia Viana Maia (1, 3) Felicien Vásquez (1)
José Eduardo Levi (4) Marilu Victoria (2)
(1) Fundação de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil (2) Fundação de
Medicina Tropical do Amazonas, Manaus, Brazil (3) Universidade Federal do Amazonas, Manaus,
Brazil (4) Universidade Estadual de São Paulo, São Paulo, Brazil
P-081 Advocacy and Piloting the First Needle and Syringe Exchange Program in Iranian
Prisons
Mohammad Shahbazi (1)* Marziyeh Farnia (1) Mohammadreza Keramati (1) Ramin Alasvand (1)
(1) Iran Prisons Organization, Tehran, Iran, Islamic Republic of
P-082 Small Intestine Enteroscopy: A New Diagnostic Tool not only in HIV Infection
Christian Traeder (1)* Julia Breitkreutz (1) Keikawus Arastéh (1)
(1) Vivantes Auguste Viktoria Hospital, Berlin, Germany
 B6: Hepatitis, Therapy
P-083 Chronic HCV Treatment with Peginterferon-Ribavirin and Severe Tuberculosis ReActivation
Roberto Manfredi (1)* Leonardo Calza (1)
P-084 Severe Psoriasis Emerged after Treatnent of Chronic HCV Co-Infection with
Pegylated-Interferon and Ribavirin, Supported by Neutropenia Rescue with Repeated
Filgrastim Administration
Roberto Manfredi (1)* Sergio Sabbatani (1)
(1) Infectious Diseases, University of Bolognna, S. Orsola Hospital, Bologna, Italy
 B7: Hepatitis, Other
P-085 The Experience of Pain Among Patients Living with Hepatitis C: an Assessment of
Prevalence and Needs
Christine Cabrera (1)* Kimberly Corace (2) Louise Balfour (2) George Tasca (2) Curtis Cooper (2)
Jonathan Angel (2) William Cameron (2) Paul MacPherson (2) Gary Garber (2)
(1) University of Ottawa, Ottawa, Canada(2) The Ottawa Hospital-General Campus, Ottawa, Canada
P-086 Spontaneous HCV Clearance in a Patient with HIV Infection and a Concurrent, Never
Treated, Evolutive HCV Hepatitis, after over Twenty Years of Chronic Co-Infection
Roberto Manfredi (1)* Nicola Dentale (1) Leonardo Calza (1)
P-087 Preventive Behavior among Doctors with Respect to Hepatitis-B in Bolan Medical
Complex Hospital, Quetta, Pakistan
Khalid Rehman (1)*
(1) Health, Quetta, Pakistan
37
POSTERS
 B8: STDs
P-088 Seroepidemiology of Infection with Herpes Simplex Virus Type 2 (Hsv2) among
Asymptomatic Students Attending Islamic Azad University of Kazeroun, Southwest of
Iran.
Daryoush Tayyebi (1)* Mojgan Tabatabaee (1) Marjan Rahsaz (2)
(1) Islamic Azad University-Kazeroun Branch, Kazeroun, Iran, Islamic Republic Of (2) Transplantation
Research Center, Shiraz, Iran, Islamic Republic Of
P-089 CANCELED
 B9: Other, Clinical Science
P-090 Disturbance of HDL Apolipoprotein AI Metabolism in Severe Hyperlipidemic and
Lipodystrophic HIV Patients on a Protease Inhibitor Treatment.
Khadija Ouguerram (1)* Yassine Zair (1) Stéphanie Billon (1) Michel krempf (1)
(1) INSERM U915, Nantes, France
P-091 Pulmonary and Disseminated Tubercular Disease by Bacillus of Calmette-Guérin
after Administration as a Local Adjuvant Immunotherapy of Relapsing Bladder
Adenocarcinoma
Roberto Manfredi (1)* Nicola Dentale (1)
P-092 Educational Intervention and HIV Infection: Preliminary Results.
Sylvie Bregigeon (1)* Brigitte Canet (1) Véronique Obry-Roguet (1) Amélie Menard (1) Isabelle
Poizot-Martin (1)
(1) 1department Of Immuno-Hematology, Hiv-Clinical Center, Hospital Sainte Marguerite, Marseilles,
France
P-093 Incidence Rate of Nosocomial Urinary Tract Infections in Intensive Care Unit Patients
of Zanjon’s Shafeeieh Hospital
Vida Sadeghzadeh (1)*
(1) Islamic Azad University ,Zanjan Branch , Zanjan, Iran, Islamic Republic Of
P-094 Hospital Based Palliative Care Approach TO HIV/AIDNT- A Nigeria Experience
Folaju Olusegun Oyebola (1)*
(1) Pain And Palliative Medicine Department. Federal Medical Centre Idi-Aba. P.M.B 3031,Sapon
P.O., Abeokuta, Nigeria
C Epidemiology & Prevention
 C1: HIV, Epidemiology & Prevention
P-095 Destruction HIV Viral RNA by SiDNA Triggering RNAse H
Karin Moelling (1)*
(1) University , Zurich, Switzerland
P-096 A Research Report on «Positive Prevention» Intervention in Two Ethnic Habitats
along the Border with Myanmar in Yunnan
Yan Guo (1) F Bin Su (1)*
(1) Yunnan Daytop Drug Abuse Treatment and Rehabilitation Center, Kunming, China
P-097 Results from a Multimedia Testing and Counseling Program in an Urban Emergency
Department
Yvette Calderon (1, 2)* Ethan Cowan (1, 2) Jade Fettig (1) Karachi Egbuta (1) Jason Leider (1, 2)
(1) Jacobi Medical Center, New York, USA (2) Albert Einstein College of Medicine, New York, USA
38
P-098 Recent HIV Infection among Newly Diagnosed with HIV Cases in Turin, Italy
Mariangela Raimondo (1)* Chiara Pasqualini (2) Valeria Ghisetti (3) Vincenza Regine (1) Laura
Camoni (1) Maria Cristina Salfa (1) Barbara Suligoi (1)
(1) Istituto Superiore di Sanità, Rome, Italy (2) SEREMI ASL 20, Alessandria, Italy (3) Amedeo di
Savoia Hospital, Turin, Italy
P-099 HIV/AIDS Epidemic Features and Trends in Setif City (Algeria) From 1986 to 2009
Amel Ouyahia (1)* Mounira Rais (1) Abdelkader Gasmi (1) Wahiba Guenifi (1) Salah Mechakra (1)
Abdemadjid Lacheheb (1)
(1) faculte de medecine centre hospitalo universitaire , setif, Algeria
P-100 HIV-Related Risk Factors among Male Sex Workers in Different Settings in
Shenzhen, China
Jin Zhao (1, 2)* Wen-De Cai (2) Lin Chen (2) Yong-Xia Gan (2) Yun-Yun Zi (2) Jin-Quan Cheng (2)
Xiao-Rong Wang (1) Ming-Liang He (1)
(1) School of Public Health of Primary Care, The Chinese University of Hong Kong, Hong Kong ,
Hong Kong (2) Shenzhen Center for Disease Control and Prevention, Shenzhen, China
P-101 The Trend of HIV/AIDS Prevalence among IDU’s in Iranian Prisoners (1376-1386)
Mohammad Shahbazi (1)* Marziyeh Farnia (1) Ghobad Moradi (1) Bahman Ebrahimi (1)
(1) GFATM(theglobalfund.org) - Iran Prisons Organization, Tehran, Iran, Islamic Republic of
P-102 HIV Infection Newly Diagnosed in Northern Italy. Evolving Trends
P-103 Men who Have Sex with Men(MSM) and HIV Epidemic in China: A Web-Based Study
on MSM
Jianmin Xing (1) Konglai Zhang (2)*
(1) Beijing University of Chinese Medicine, Beijing, China (2) Peking Union Medical College, Beijing,
China
P-104 CANCELLED
P-105 Killer Immunoglobulin-Like Receptor Genes and Heterosexual HIV-1 Transmission
Aimee Merino (1)* Rakhi Malhotra (1) Matt Morton (1) Joseph Mulenga (2, 3) Susan Allen (2, 3)
Eric Hunter (3) Jianming Tang (1) Richard Kaslow (1)
(1) UAB, Birmingham, USA (2) Rwanda-Zambia HIV Research Group, Lusaka, Zambia (3) Emory,
Atlanta, USA
P-106 Non-Injected Illicit Drugs and Alcohol and HIV-Related High-Risk Sexual Behaviors in a
Street-Recruited Sample of Non-Injecting Drug Users in New York City
Ashutosh Mishra (1)* Daniel Pilowsky (1) Judith Jacobson (1)
(1) Columbia University, New York, USA
P-107 A Validated Stigma Scale Measures Decreased HIV-Related Stigma Among Men in a
Community-Based HIV Prevention Services Program in Rural Maharashtra, India.
Ashok Dyalchand (1)*
(1) Institute of Health Management, Pachod, Pune, India
P-108 Difficulties of Routine Rapid HIV Screening in Emergency Department
Philippe Genet (1)* Catherine Legall (1) Pascal Peudepiece (1) François Briand (1) Laurence
Courdavault (1)
(1) CH Victor Dupouy, Argenteuil, France
P-109 CANCELLED
39
POSTERS
P-110 Subacute and Rehabilitation Care Facilities « Soins de Suite et De Réadaptation
(SSR) », Dedicated to HIV Patients in Marseilles,France
Jean-Paul Dimet (1) Gabrielle Vinai (1) Berengère Labarrière (1) Loïc Julien (1) Eliane Lerda (1)
Nadia Timezouaght (1) Nathalie Petit (1)*
(1) Polyclinique La Feuilleraie, Marseille, France
P-111 Identifying Practices and Strategies to Increase HIV Testing among Haitian Migrant
Communities
Jonathan Santiago (1, 2)*
(1) Agence de la santé et des services sociaux de Montréal, Montréal, Canada(2) University of
Washington School of Public Health, Seattle, USA
P-112 HIV/AIDS Epidemic in Belarus
Vladimir Eremin (1)* Elena Gasich (1) Sergei Eremin (1) Ekaterina Ambarcumian (1) Vladimir
Lukashov (3)
(1) Research Institute for Epidemiology & Microbiology, Minsk, Belarus(2) D.I. Ivanovsky Institute
of Virology, Moscow, Russian Federation(3) Academic Medical Center, University of Amsterdam,
Amsterdam, The Netherlands
P-113 Cervical Dysplasia in Postmenopausal Patients Infected by HIV.
Pierre-François Ceccaldi (1, 2)* Claudia Ferreira (1) Florence Coussy (1) Charlotte Mechler (1)
Catherine Crenn-Hebert (1) Laurent Mandelbrot (1)
(1) AP-HP Louis Mourier, Colombes, France(2) AP-HP Beaujon, Clichy, France
P-114 CANCELLED
P-115 Knowledges, Attitudes and Practices in University Students about Sexual and
Reproductive Health and HIV/AIDS in Bogotá D.C., Colombia
Oscar David Diaz-Sotelo (1)*
(1) Universitat Autònoma de Barcelona, Barcelona, Spain(2) RANDOM Foundation, Bogotá D.C.,
Colombia
P-116 Transition to Adult Clinics in Youth Living with HIV since Birth
Mylène Fernet (1)* Marie-Eve Richard (1) Joseph Josy Lévy (1) Joanne Otis (1) Lapointe Normand
(2) Samson Johanne (2) Guylaine Morin (2) Kimberly Wong (1) Jocelyne Thériault (1) Germain
Trottier (3)
(1) Université du Québec à Montréal, Montréal, Canada (2) CHU Ste-Justine, Université de
Montréal, Montréal, Canada(3) Université Laval , Québec, Canada
P-117 Knowledge and Attitudes on HIV/AIDS and Sexual Behaviour among Male Soldiers in
Sri Lanka Army
Saveen Semage (1)* Sujatha Samarakoon (2)
(1) Sri Lanka Army Medical Services, Colombo, Sri Lanka(2) National STD/AIDS Control Program,
Ministry of Healthcare & Nutrition Sri Lanka, Colombo, Sri Lanka
P-118 Female Condom in HIV/AIDS Prevention among Female Commercial Sex Workers in
Nigeria: A Geographical Perspective
Emmanuella Onyenechere (1)*
(1) Imo State University, Owerri, Nigeria
P-119 Human Immunodeficiency Virus Viral Markers Seroperevalence in First-Time Healthy
Blood Donors Refered to Transfusion Centers of Bushehr Province, South of Iran
(April2004 to March2008)
Hesam_oddin Maneshi (1)* Mojtaba Karimi (2) Shahab Zare (1) Gholam Reza Hajiani (2)
(1) Bushehr University of Medical Sciences - Student’s Research Committee, Bushehr, Iran, Islamic
Republic of(2) Bushehr Blood transfusion organization, Bushehr, Iran, Islamic Republic of
40
P-120 Correlates of HIV Knowledge and Sexual Risk Behaviors among Female Military
Personnel
Ekere Essien (1)* Osaro Mgbere (1, 2) Ernest Ekong (1, 3) Susan Abughosh (1) Emmanuel Monjok
(1)
(1) University of Houston, Houston, USA (2) Houston Department of Health and Human Services,
Houston, USA (3) Institute for Health Research and Development, Lagos, Nigeria
P-121 Ethnological Inquiry into Sexual Behaviours at Risk to Homosexuals in Portugal
Marta Maia (1)* Khalid Fekhari (2)
(1) CRIA - ISCTE, Lisbon, Portugal(2) Instituto Piaget, Viseu, Portugal
P-122 Stigma and HIV Risk Behaviors of Transgender Women in Nepal: Implications for HIV
Prevention
Erin Wilson (1)* Sunil Babu Pant (2)
(1) Center for AIDS Prevention Studies, San Francisco, USA (2) Blue Diamond Society, Kathmandu,
Nepal
P-123 Seroprevalence of Hepatitis B- Surface Antigen among Non-Professional Blood
Donors in Selected Hospital in Dhaka City.
Rezaul Karim (1)*
(1) NIPSOM, DHAKA, Bangladesh
P-124 HIV Prevalence Among TB Patients Attending Dots Centres in Rural Haryana, India
Ravi Kumar Balu (1)* Sanjay Rai (1) Shashi Kant (1) Krishnan Anand (1) Lalit Dar (1) Urvashi Singh
(1)
(1) All India Institute of Medical Sciences, New Delhi, India
P-125 Factor Associated with Getting HIV Tested for Infant whose Born from HIV Infected
Mothers, Thailand : 2008
Pradabporn Duangajna (1)*
(1) Ofice of Disease Prevention and Control Region 3 Chonburi Thailand, Chonburi, Thailand
P-126 Condom Use and Sexual Partnerships among Truck Drivers in Southern Brazil
Daniela Knauth (1) Andréa Fachel Leal (1) Flavia Pilecco (1)*
(1) UFRGS, Porto Alegre, Brazil
P-127 CANCELLED
P-128 HIV Infection and the Immigration in Italy. Consequences on Inpatient Hospitalizations
and Day-Hospital Admissions at a A Metropolitan Hospital, during the Last Nine
Years
P-129 The Implementation of EPP Software using HIV Prevalence Data from Studies
Conducted in Greece
Georgios Nikolopoulos (1)* Chryssa Tsiara (1) Chryssoula Botsi (1)
(1) Hellenic Centre For Diseases Control And Prevention, Amarousio, Greece
P-130 HIV/AIDS Related Knowledge and Attitude among Female Sex Workers in Tehran/Iran
Saeid Madani Ghahfarokhi (1)* Ameneh Setareh Forouzan (1) Payam Roshanfekr (1, 1, 1)
Mohamad Ali Mohammadi (1) Masoumeh Dejman (1) Meroeh Vameghi (1) Mirtaher Mousavi (1)
Hassan Rafiee (1) Mansoureh Hemmasian Ettefagh (1) Malihe Sheyani (2)
(1) Social Welfare and Rehabilitation Sciences University, Tehran, Iran, Islamic Republic of (2) social
sciences department, Tehran, Iran, Islamic Republic of
41
POSTERS
P-131 CANCELLED
P-132 CANCELLED
P-133 Problem of Nosocomial Infection with Hepatitis B, C Viruses and HIV in Russian
Dental Institutes. Review.
alexey shatokhin (1)*
(1) City AIDS Center, Moscow, Russian Federation
P-134 Feto-Maternal Outcomes in HIV Positive Pregnant Women: Pakistan PPTCT Experience
shazra abbas (1)* naveeda shabbir (1)
(1) National AIDS Control program Pakistan, Islamabad, Pakistan
P-135 An Analysis of Non Response in HIV Testing in India: Evidences from National Family
Health Survey -3
Shri Kant Singh (1)*
(1) International Institute for Population Sciences, Mumbai, India
P-136 The Evaluation of Peer Education Workshops Efficacy on Knowledge of Non Medical
Students About HIV/AIDS , Bushehr, South of Iran
Hesam_oddin Maneshi (1)* Ismaeil Asaadi (1)
Republic of
P-137 Determinants Of the Willingness-To-Pay For HIV/AIDS Prevention: The Case Of
Mother-To-Child Transmission In Selected Hospitals In Ghana
Emmanuel Ayifah (1)*
(1) University of Ghana, Accra, Ghana
P-138 Knowledge and Attitudes of Students in an Offshore Caribbean Medical School
Towards HIV/AIDS
Rotimi Orisatoki (1)* Oluwafemi Oguntibeju (1, 1)
(1) Spartan Health Sciences University, School of Medicine, Vieux Fort, Saint Lucia (2) Cape
Peninsula University of Technology, Bellville 7535, South Africa
P-139 Creating a Supportive Environment is Very Important to Reduce STI, HIV/AIDS and
Infectious Disease.
S.M Rezaul Islam (1)* Nahida Islam (1)
(1) SHED Foundation, Chittagong, Bangladesh
P-140 Civic Educating Rural Pregnant Mothers to Take Full Nevaripine Dose a Tool to
Reducing HIV Prevalence in Malawi
Caleb Kondwani Faith Thole (1)*
(1) Global Hope Mobilization, Lilongwe, Malawi(2) International AIDS Society, Geneva, Switzerland (3)
Equinet, Soutthern Africa, Zimbabwe
P-141 A Study of HIV/AIDS Related Knowledge and Attitudes amongst the Engineering
College Students
Arjit Kumar (1)* Pankaj Bharadwaj (1) J.P Srivastava (1)
(1) Eras Lucknow Medical College And Hospital, Lucknow, India
P-142 Services Integration for Injection Drug Users on Antiretroviral Therapy for
Management of HIV Epidemic in Estonia
Kaja-Triin Laisaar (1)* Anneli Uusküla (1) Anjali Sharma (2) Jack DeHovitz (2)
(1) Department of Public Health, University of Tartu, Tartu, Estonia (2) Downstate Medical Center,
State University of New York, Brooklyn, USA
42
P-143 The International Physical Activity Questionnaire Overestimates Moderate and
Vigorous Physical Activity in Human Immunodeficiency Virus Compared with
Accelerometry
Soula Fillipas (1, 2)* Flavia Cicuttini (1, 2) Catherine Cherry (1, 2, 3) Anne Holland (1, 4)
(1) The Alfred, Melbourne, Australia(2) Monash University, Melbourne, Australia (3) Burnet
Institute, Melbourne, Australia (4) La Trobe University, Bundoora, Australia
P-144 The Perception of Taxi Drivers in Southern Part of Saint Lucia, West Indies Towards
HIV/AIDS and Condom Use
Rotimi Orisatoki (1)* Oluwafemi Oguntibeju (2)
(1) Spartan Health Sciences University, School of Medicine, Vieux Fort, Saint Lucia (2) Cape
Peninsula University of Technology, Bellville 7535, South Africa
P-145 Interventions and Strategy to Mitigate HIV Related Risk Behavior Among Young Men
in India
Vipul Vipul (1)* Srikant Srikant (1)
(1) IIPS, Mumbai, India
P-146 Increased Antenatal HIV Testing among Rural Pregnant Women: a Community-Based
HIV Prevention Services Program in Rural Maharashtra, India.
Ashok Dyalchand (1)* Gita Sinha (1)
(1) Institute of Health Management Pachod , Pune , India
P-147 Effect of Materials on HIV/AIDS by the Different Segment of Population in a Selected
Community Area.
Rezaul Karim (1)*
(1) NIPSOM, DHAKA, Bangladesh
P-148 Assessing Risk Criteria and HIV Prevalence in Antenatal Clinic Clients from 2 Urban
Tertiary Hospitals in Pakistan
Naveeda Shabbir (1)* Qudsia Uzma (1) Shazra Abbass (1)
(1) National AIDS Control Programme, Islamabad, Pakistan
P-149 Develop IEC Material by PLHA to Lead a Positive Life.
Santosh Chettri (1)*
(1) National Association of People living with HIV/AIDS in Nepal (NAP+N), Kathmandu, Nepal
 C2: Hepatitis, Epidemiology & Prevention
P-150 Service Integration of Blood Borne Viral Infections in HIV/AIDS Prevention Sites
Steven McCadney (1)*
(1) Yeshiva University, New York City, USA
P-151 HBV and HCV Viral Markers Seroperevalence in First-Time Healthy Blood Donors
Refered to Transfusion Centers of Bushehr Province, South of Iran (April2004 to
March2008)
Hesam_oddin Maneshi (1)* Shahab Zare (1) Mojtaba Karimi (2) Gholam Reza Hajiani (2)
Republic of(2) Bushehr Blood transfusion organization, Bushehr, Iran, Islamic Republic of
P-152 Protecting at Risk Cadres of Health Workers from Medical Transmission of HIV and
Hepatitis B and C Through Injection Safety Interventions
Susana de la Torre (1) Innoncent Gasimbi (2)* Deepa Bhat (1) Jessica Posner (1) Megan Noel (1)
Victoria Masembe (2) Jackson Songa (3) Iqbal Hossain (1)
(1) John Snow Inc., Arlington, USA (2) John Snow Inc., Kampala, Uganda (3) John Snow, Inc.,
Nairobi, Kenya
43
POSTERS
P-153 Awareness about Hepatitis B Infection among the Grass Root Level Health and
Family Planning Workers in a Selected Health Complex at Dhaka District.
Rezaul Karim (1)*
(1) NIPSOM, Dhaka, Belarus
P-154 Seroprevalence of Hepatitis B-Surface Antigen Among Selected Group of Population
Rezaul Karim (1)*
(1) NIPSOM, Dhaka, Bangladesh
 C3: Other, Epidemiology & Prevention
P-155 Home Visiting to an HIV Positive Patient Prior to Initiation of Haart Has Lasting
Impact on Their Adherence. Taso Experience.
Emmanuel Odeke (1)* Ricky Jones Nyatia (1, 1) Peter Sekiranda (1, 1)
(1) The AIDS Support Organisation (TASO), Kampala, Uganda
P-156 Prevention by Care and Treatment of HIV-Positive Pregnant Woman in Côte D’ivoire
Kouamé Hervé Aka Prao (1)* Nicole Dakoury (1, 1) Pety Touré (1, 1) Nafissa Diakité (1) Koko
Régina Konan (1) Marie-france Coulibaly Anaky (1) Siaka Touré (1, 1) Irma Ahoba Bobo (2)
P-157 A Model to Determine Effective HIV/AIDS and Multi-Drug Tuberculosis (MDRTB)
Treatment Policies: A Case Study from the Russian Federation
Reda Lebcir (1)*
(1) University of Hertfordshire, Hatfield, UK
P-158 Sexual Behaviours and Drug Use among the Street Children
Shyam Lamsal (1)*
(1) B.P.Koirala Institute of Health Sciences, Dharan, Nepal
P-159 Hospitalization Potential at an Infectious Diseases Division of a Metropolitan Hospital
of Northern Italy. Persisting Limitations and Related Problems
P-160 HIV/AIDS and Human Rights in Legislation of the Republic of Serbia
Miljana Grbic (1)* Vojin Dimitrijevic (2) Nenad Petkovic (3) Ana Maricic (4) Judita Reichenberg (5)
Jelena Zajeganovic (5) Milos Stojanovic (1) Rade Grbic (6)
(1) UNAIDS, Belgrade, Serbia (2) Beogradski centar za ljudska prava, Belgrade, Serbia (3) Q-klub,
Belgrade, Serbia (4) Ministry of Justice, Belgrade, Serbia(5) UNICEF, Belgrade, Serbia (6) Medical
Faculty Pr, Pristina, Serbia
P-161 Supporting Homeless People Living with HIV
Ailsa Cameron (1)*
(1) University of Bristol , Bristol , UK
P-162 Difficulties to Implement a Support Group for HIV Patients
Julia Artur (1)* Philippe Genet (1) Agathe Pigeon (1) Tahar Touarhi (1)
(1) CH Argenteuil, Argenteuil, France
44
D Pharmacology
 D1: HIV, New Drugs
P-163 Allosteric Regulation by Non Peptidic, Low Molecular Weight Compounds of CCR5
Coupling to G-Proteins and Interaction with GP120 - Consequences on Inhibition of
R5 HIV-1 Infection.
Patricia Rueda (1)* Javier Garcia-Perez (1, 2) Isabelle Staropoli (1) Esther Kellenberger (3) José
Alcami (2) Fernando Arenzana-Seisdedos (1) Bernard Lagane (1)
(1) Institut Pasteur, Paris, France (2) Instituto de Salud Carlos III, Madrid, Spain (3) Université Louis
Pasteur, Strasbourg, France
P-164 Modulations of Human Placental Transfer of Lopinavir, Ritonavir and Enfuvirtide.
Pierre-François Ceccaldi (1, 2, 3)* Laurent Mandelbrot (3) Claudia Ferreira (3) Robert Farinotti (1)
Francois Forestier (1) Sophie Gil (1)
(1) Department of Clinical Pharmacy, University Paris-Sud 11, IFR141, School of Pharmacy,
Châtenay-Malabry, France (2) Department of Obstetrics and Gynecology, Beaujon Hospital, APHP, Clichy, France (3) Department of Obstetrics and Gynecology, Louis Mourier Hospital, AP-HP,
Colombes, France
P-165 CANCELLED
P-166 Duration of Antiretroviral Regimens in Treatment-Experienced Patients in Clinical
Practice
Vicente Escudero Vilaplana (1)* Sergio Plata Paniagua (1) Nicolas Trovato Lopez (1) Isabel Castillo
Romera (1) Arantza Ais Larisgoitia (1) Jose Maria Bellon Cano (1) Maria Sanjurjo Saez (1)
(1) Hospital General Universitario Gregorio Marañon, Madrid, Spain
 D3: Therapeutic Drug Monitoring
P-167 A Model Using Adherence: House Compliance Center Oasis AAS
Abdoulazziz Soundiata Traoré (1)*
(1) Association African Solidarité, Ouagadougou, Burkina Faso
E Emerging Infectious Diseases
 E1: Laboratory Aspects
P-168 Scorpion Model of Influenza A/H1N1: Hemagglutinin (Ha) Contains A Scorpion Toxin,
Binding To Voltage-Gated Sodium Na+ Channel: Na+ Channel Inhibitors as Therapy.
Guy Mong Ky Tran (1, 2)* Laurent Gerbaud (1) Adrien Caprani (2)
(1) University of Auvergne, Hotel-Dieu Hospital, Clermont-Ferrand, France(2) Association POSITIFS,
Paris, France
P-169 Development of a Test System for Simultaneous Detection of HIV RNA and Hepatitis
C Virus (HCV) and DNA of Hepatitis B Virus (HBV) in Blood Samples
Nader Shahrokhi (1)* Masoud Hajia (2) Maysam Shahrokhi (2) Foroozan Abbasi (2) Mohamad
Farzaneh-Khah (2)
(1) Pasteur Institute of Iran, Tehran, Iran, Islamic Republic of (2) Noor Medical Laboratory, Tehran,
Iran, Islamic Republic of
P-170 Analyses Reveal a Novel Avirulent Streptococcus Suis Serotype 2 Strain that Induces
Protective Immunity Against Challenge with the Highly Virulent Strains
Jiaqi Tang (1)*
(1) Department of Epidemiology, Research Institute for Medicine of Nanjing Command, Nanjing,
China
45
POSTERS
P-171 A Prospective Project of Microbiological Surveillance at a Teaching Hospital in Italy.
Evolving Epidemiological Features, and in vitro Antimicrobial Sensitivity Trends
P-172 A Prospective Microbiological Surveillance in a Teaching Italian Hospital. Microbial
Isolations and in vitro Antimicrobial Susceptibility Levels, and their Modifications Over
Time
(1) Infectious Diseases, University of Bologna, Bologna, Italy
P-173 Auto-Immune Thrombocytopenia after Measles Mumps Rubella MMR Vaccination:
Molecular Mimicry of Measles Virus Phosphoprotein with Platelet GPIIB.
Guy Mong Ky Tran (1, 2)* Laurent Gerbaud (1) Adrien Caprani (2)
(1) University of Auvergne, Hotel-Dieu Hospital, Clermont-Ferrand, France (2) Association Positifs, Paris,
France
P-174 Urinary Tract Pathogens Among Inpatients at a Large Italian Tertiary Care Hospital.
A Prospective Monitoring Study
P-175 Agents Causative of Sepsis-Bacteremia in a Four-Year Prospective Surveillance Study
Carried Out at a Teching Italian Hospital
 E2: Clinical Aspects
P-176 The Emerging and the Spread of the Fifth Plasmodium Responsible of Human
Malaria: Plasmodium Knowlesi
Roberto Manfredi (1)* Sergio Sabbatani (1) Sirio Fiorino (1, 2)
(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy (2) Department of
Internal Medicine, Budrio, Italy
P-177 Perceived Quality of Clinical Care Provided by Nurses to People Living with HIV at
Four Taso Sites in Uganda
Kenneth Mugisha (1, 2)* Coutinho Alex (2)
(1) TASO, Kampala, Uganda (2) IDI, Kampala, Uganda
P-178 An Increasing Pathomorphism of Pulmonary Tuberculosis. Is There a Therapeutic
Role for Novel Antimicrobial Compounds Effective on Mycobacterium Tuberculosis?
Roberto Manfredi (1)* Sergio Sabbatani (1) Leonardo Calza (1)
P-179 Symptomatic, Prolonged Parvovirus B19 Infection and Accompanying Illness in
Otherwise Healthy Adults
P-180 An Infectious Disease Day-Hospital Service in a Metropolitan Area of Northern Italy.
Evolving Assistance Features in the Last Fifteen Years (1994-2008)
46
 E4: Other, Emerging Infectious Diseases
P-181 Is There Pre-Existing Cross-Reactivity to Influenza A(H1N1)2009 in a Tropical
Population?
Kwai Peng Chan (1)* Yee Leng Lee (1) Xin Lai Bai (1) Siew Hoon Lim (1)
(1) Singapore General Hospital, Singapore, Singapore
P-182 Molecular Epidemiology of Chikungunya Strains in Singapore in 2008
Kim-Yoong Puong (1)* Kwai-Peng Chan (1)
(1) Singapore General Hospital, Singapore, Singapore
P-183 Synthesis of the Studies About the Transmission Cycle of Malaria in an Area of Very
Low Incidence Outside the Amazon Region in Brazil
Crispim Jr Cerutti (1)* Aloísio Falqueto (1) Helder Ricas Rezende (4) Renata Soares (2) Isabel Alves
(2) Delsio Natal (2) Paulo Roberto Urbinatti (2) Tasciane Yamasaki (2) Ana Maria Ribeiro de Castro
Duarte (3) Rosely dos Santos Malafronte (2)
(1) Universidade Federal do Espírito Santo, Vitória, Brazil (2) Universidade de São Paulo, São Paulo,
Brazil (3) Superintendência de Controle de Endemias, São Paulo, Brazil (4) SESA, Vitória, Brazil
P-184 Clinical Presentation of Influenza A (H1N1) Infection in a Local Emergency
Department in Greece.
Evangelos Voudoukis (1) Athanasios Panoutsopoulos (1) Pappas Apostolos (1) Stofa Efthimia
(1) Leventogianni Vassiliki (1) Mpoumpoukas Theodoros (1) Mylona Panagiota (1) Rozi Fotini (1)
Andrianopoulos Ioannis (1) Andrianopoulos Georgios (1)*
(1) Department of internal medicine of General Hospital of Argos, argos, Greece
P-185 Comparison Of A Novel Real-Time RT-PCR, NS1 Antigen Detection And Serology In
Early Diagnosis Of Dengue In Travelers.
Eili Huhtamo (1)*
(1) University of Helsinki, Helsinki, Finland
P-186 Influence Of Water On The Circulation Of The West Nile Virus In Horses In Southern
France
Sophie Pradier (1, 2)* Alain Sandoz (3) Gaëtan Lefebvre (3) Annelise Tran (4) Sylvie Lecollinet (5)
Agnès Leblond (2, 6)
(1) Clinique équine ENVA, Maisons-Alfort, France (2) UR 346 Epidémiologie animale INRA, Saint
Genès Champanelle, France (3) Tour du Valat, Arles, France (4) CIRAD Agirs, Montpellier, France
(5) UMR 1161 Virologie INRA AFSSA ENVA, Maisons-Alfort, France(6) Clinéquine ENVL, Marcy
l’étoile, France
P-187 An Outbreak Of Influenza A (H1N1) 2009 At Mae Fah Luang University, Chiang Rai
Province, Northern Thailand
Tawatchai Apidechkul (1)*
(1) Mae Fah Luang University, Chiang Rai Province, Thailand
P-188 Adherence To The Treatment Of Individuals With The HIV/Tuberculosis Co-Infection:
Integrative Review
Lis Neves (1) Renata Reis (2) Elucir Gir (1)* Patrícia Ribeiro (1)
(1) São Paulo University - School Of Nursing De Ribeirão Preto , Ribeirão Preto, Brazil (2) Alagoas
University, Maceió, Brazil
P-189 HIV & Emerging Infectious Diseases In Mobile Populations In Europe
Anna-Paola de Felici (1)* Manuel Carballo (1) Sofiat M.Akinola (1)
(1) International Centre for Migration, Health and Development, Geneva, Switzerland
47
POSTERS
P-190 Serum Levels Of Inflammatory Cytokines In Leprosy Patients
Lúcia de Paula (1)* Isabella Motta Passos (1) Rossilene Conceição da Silva (1) Adriana Malheiro (2)
George Allan Villarouco Silva (1) Maísa Porto dos Santos (1) Maria da Graça Souza Cunha (1)
(1) Fundação Alfredo da Matta, Manaus, AM, Brazil (2) Fundação de Hematologia e Hemoterapia
do Amazonas, Manaus, AM, Brazil
P-191 Detection Of Ovine Herpesvirus-2 In Swine Semen, Brazil
Erica Azevedo Costa (1)* Aline de Marco Viott (1) Glauber de Souza Machado (1) Maria Rosa
Quaresma Bomfim (1) Fabiana Magalhães Coelho (1) Mauricio Resende (1) Roberto Mauricio
Carvalho Guedes (1)
(1) Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
P-192 Multiple, Concurrent Or Subsequent Dysreactive And Autoimmune Disorders.
Potential Clinical-Patogenetic Correlations, And Systemic Infectious Complications
48
AUTHORS INDEX
INDEX DES AUTEURS
A
Asaadi I........................................... P-136
Abbas S.......................................... P-134
Aweeka F............................................ I-08
Abbasi F.......................................... P-169
Ayifah E...........................................P-137
Abbass S......................................... P-148
Azevedo Costa E.............................. P-191
Abbate I............................................ O-11
Abughosh S..................................... P-120
B
Adrien A.......................................... P-111
Back D............................................... I-10
Agochukwu C................................... P-073
Badsi E............................................. O-10
Agu K.............................................. P-054
Bai X. L........................................... P-181
Ahoba Bobo I................................... P-156
Baldanti F.......................................... O-16
Ais Larisgoitia A.............................. P-166
Balfour L......................................... P-085
Aka Prao K. H................................. P-156
Balu R. K........................................ P-124
Alarcón J........................................ P-046
Barreio P........................................... O-13
Alasvand R...................................... P-081
Barreiro P.............................P-051, P-076
Albalate M...................................... P-076
Bartolini B........................................ O-11
Alcami J...................................I-15, P-163
Battaglia F........................................ O-06
Alex C............................................. P-177
Baumert T. F.................................... P-007
Allan Villarouco Silva G.................... P-190
Bavari S.......................................... P-004
Allen S............................................ P-105
Bello L............................................. P-063
Almasi F.......................................... P-016
Bellon Cano J. M............................. P-166
Alvarez E......................................... P-076
Bergmann J. F................................... O-10
Alves I............................................. P-183
Bertuccio M. P.................................P-022
Amabile T.........................................P-031
Bevilacqua G.................................... P-002
Amatya S........................................ P-003
Bharadwaj P.....................................P-141
Ambarcumian E................................P-112
Bhat D............................................ P-152
Amin B....O-14, P-049, P-053, P-065, P-075
Billon S........................................... P-090
Anand K.......................................... P-124
Blanco F............................................ O-13
Angel J............................................P-085
Blasi M........................................... P-029
Antonelli G.......................................P-042
Blazkova J......................................... O-04
Antonelli L....................................... P-042
Bomsel M........................................ P-023
Apidechkul T.....................................P-187
Botsi C............................................ P-129
Apostolos P......................................P-184
Botta M............................................ O-16
Appay V.............................................. I-30
Bourinbaiar A...................................P-030
Araripe Sucupira M. C......................P-050
Bourliere M........................................ I-24
Arastéh K........................................P-082
Bourry O......................................... P-011
Araújo A. R...................................... P-031
Bras M............................................. O-05
Arenzana-Seisdedos F....................... P-163
Bregigeon S.......................... P-059, P-092
Argentini C...................................... P-029
Breitkreutz J................................... P-082
Armstrong C..................................... O-08
Brenner B.G....................................... I-21
Arribas J........................................... O-15
Brew B............................................... I-07
Artur J............................................P-162
Briand F.......................................... P-108
49
AUTHORS INDEX
INDEX DES AUTEURS
Briand S............................................. I-03
Chen L.................................... O-03, P-100
Brooks C............................................ I-28
Cheng J. Q..............................O-03, P-100
Bruselles A........................................O-11
Cherry C......................................... P-143
Buonaguro F....................................... I-22
Chettri S......................................... P-149
Buonaguro L....................................... I-33
Chionne P........................................ P-029
Burruano D. L..................................P-001
Chirico C......................................... P-022
Busch M.P.......................................... I-28
Chow V............................................ P-037
Cicuttini F........................................ P-143
Cioni M. P........................................P-002
Clayton R........................................ P-024
C
Coiras M............................................ I-15
Cabrera C....................................... P-085
Conceição Da Silva R........................P-190
Cafaro V.......................................... P-037
Cooper C......................................... P-085
Cai W. D.......................................... P-100
Corace K......................................... P-085
Cairo C..............................................O-08
Corazza F........................................ P-026
Calderon Y....................................... P-097
Corneau A.......................................... I-32
Calviño A......................................... P-051
Coulibaly Anaky M. F........................ P-156
Calza L.......................P-083, P-086, P-178
Courdavault L........................P-047, P-108
Cameron A...................................... P-161
Coussy F..........................................P-113
Cameron W..................................... P-085
Cowan E.......................................... P-097
Camoni L......................................... P-098
Crenn-Hebert C............................... P-113
Canet B........................................... P-092
Capeau J............................................ I-06
D
Capobianchi M. R...............................O-11
Dakoury N....................................... P-156
Caprani A............................. P-168, P-173
Dalai S............................................ P-020
Carballo M...................................... P-189
Dalton H............................................. I-01
Cardoso S....................................... P-039
Damesyn M....................................... O-01
Carrilho C........................................P-002
Dar L.............................................. P-124
Castillo Romera I............................. P-166
De Falco G....................................... P-070
Castrighini C................................... P-066
De Felici A. P................................... P-189
Castro Á......................................... P-063
De La Torre S.................................. P-152
Catellani S.............................. O-06, P-025
De Marco Viott A............................ P-191
Catone S......................................... P-029
De Souza Machado G....................... P-191
Catteeuw D..................................... P-024
Debre P.............................................. I-32
Cau P................................................. I-29
Deeks S.G...........................................I-28
Cavalieri E....................................... P-050
Dehovitz J....................................... P-142
Ceccaldi P. F......................... P-113, P-164
Dejman M........................................ P-130
Ceccherini-Silberstein F....................... I-20
Dejucq-Rainsford N...........................P-011
Cerutti C. J..................................... P-183
Deleage C........................................ P-011
Chabert-Orsini V.................................O-12
Demetriou V. L.................................P-028
Chan K. P............................. P-181, P-182
Denis H........................................... P-011
50
Dental C.......................................... P-007
Farinotti R.......................................P-164
Dentale N............................. P-086, P-091
Farnia M...............................P-081, P-101
Derasari U....... O-14, P-049, P-053, P-065,
P-075
Farzaneh-Khah M............................. P-169
Dereuddre-Bosquet N.......................... I-32
Descoutures J. M............................ P-078
Dettori S......................................... P-029
Diakité N......................................... P-156
Diaz-Sotelo O. D.............................. P-115
Dimet J. P....................................... P-110
Dimitrijevic V................................... P-160
Diniz Pimentel J. P................ P-031, P-080
Dmitry P..........................................P-030
Dos Santos Malafronte R................ P-183
Drillet A. S...................................... P-023
Duangajna P.................................... P-125
Duchateau J.................................... P-026
Durando P....................................... P-025
Dyal J............................................. P-020
Dyalchand A..........................P-107, P-146
Dyner T........................................... P-037
Fasulo G.......................................... P-041
Faucher O........................................P-059
Fausther-Bovendo H............................ I-32
Favorov M......................................... O-09
Fekhari K........................................ P-121
Fenoglio D...............................O-06, P-025
Fernandes L.....................................P-074
Fernandez J. V................................... O-13
Fernandez Lopez L........................... P-050
Fernet M......................................... P-116
Ferreira C............................. P-113, P-164
Ferreira D....................................... P-039
Ferrera A........................................ P-025
Fettig J........................................... P-097
Fillipas S......................................... P-143
Fiorino S..........................................P-176
Firaguay G....................................... P-007
Fisher M............................................. I-04
Flood J.............................................. O-01
E
Florentin J.......................................P-007
Ebrahimi B...................................... P-101
Efthimia S....................................... P-184
Egbuta K......................................... P-097
Egwang T......................................... P-072
Ekong E...........................................P-120
Forestier F...................................... P-164
Forouzan A. S.................................. P-130
Fotini R........................................... P-184
Fulgaro C..............................P-040, P-041
Futoshi Yamamoto J........................ P-050
Emu B................................................ I-28
Eremin S......................................... P-112
Eremin V......................................... P-112
Escudero Vilaplana V........................P-166
Essien E.......................................... P-120
G
Gallo R.............................................. KL-1
Galvão M......................................... P-066
Gameiro Da Fonseca Pachi C............ P-050
Gan Y. X.......................................... P-100
F
Garbelli A.......................................... O-16
Facer M............................................ O-01
Garber G......................................... P-085
Fachel Leal A................................... P-126
Garcia N..........................................P-031
Fairon Y...........................................P-055
Garcia-Perez J................................. P-163
Falasca F......................................... P-042
Gasich E.......................................... P-112
Falasca K..............................P-062, P-064
Gasimbi I......................................... P-152
Falchi F............................................. O-16
Gasmi A.......................................... P-099
Falqueto A....................................... P-183
Gasperini R......................................P-025
51
AUTHORS INDEX
INDEX DES AUTEURS
Genet P........... P-047, P-078, P-108, P-162
Hoffmann S..................................... P-018
Genovese D..................................... P-029
Holland A........................................ P-143
Georgios A...................................... P-184
Hopewell P........................................ O-01
Gerbaud L............................. P-168, P-173
Hossain I......................................... P-152
Gerbe J........................................... P-047
Hsue P.Y............................................. I-28
Ghisetti V........................................ P-098
Huhtamo E...................................... P-185
Gil S................................................ P-164
Hunt P................................................ I-28
Giorgetti C........................................ O-12
Hunter E......................................... P-105
Gir E.....................................P-066, P-188
Huskens D....................................... P-017
Gondois-Rey F............... O-04, P-007, P-008
Gonzalez-Lahoz J................................ O-13
I
Goodier M.R....................................... I-14
Ientile R.......................................... P-022
Goubau P......................................... P-055
Ioannis A......................................... P-184
Gougeon M. L........................... O-05, O-07
Grangé J......................................... P-078
Graziano F....................................... P-042
Islam S. R....................................... P-139
Israelski D....................................... P-020
Iversen P......................................... P-004
Graziosi C........................................ P-021
Grbic M........................................... P-160
Grbic R............................................P-160
Guenifi W.........................................P-099
Guglietta S...................................... P-021
Guidotti G........................................P-002
Guillaume M. P.................................P-026
Guo Y.............................................. P-096
Gutiérrez C......................................P-046
Gwokyalya V.................................... P-057
H
Hajia M........................................... P-169
Hajiani G. R........................... P-119, P-151
Halfon P............................................ O-12
Hallenberger S.................................P-024
Hatano H............................................ I-28
Hayashido M................................... P-066
He M. L.................................. O-03, P-100
Hejnar J............................................ O-04
Hemmasian Ettefagh M................... P-130
Henrivaux P..................................... P-055
Herrera D........................................P-008
Hill A................................................. O-15
Hill J................................................. O-01
Hirsch I........................ O-04, P-007, P-008
J
Jacobson J...................................... P-106
Jaye A............................................. P-009
Jégou B........................................... P-011
Jirathitikal V.................................... P-030
Johanne S....................................... P-116
Jonas E........................................... P-018
Josy Lévy J...................................... P-116
Julien L........................................... P-110
K
Kabamba B...................................... P-055
Kamya M.........................................P-043
Kant S............................................ P-124
Karim R...........P-123, P-147, P-153, P-154
Karimi M.............................. P-119, P-151
Karmali R........................................ P-026
Karomba J............................ P-038, P-056
Kaslow R......................................... P-105
Kassaye S....................................... P-020
Katabira E....................................... P-035
Katz A............................................. P-111
Katzenstein D................................. P-020
Kavina B. O-14, P-049, P-053, P-065, P-075
52
Kellenberger E................................. P-163
Leider J........................................... P-097
Keramati M..................................... P-081
Leonciks A....................................... P-044
Kettoola S....................................... P-015
Leoncini L........................................ P-070
Khanlou H........................................P-048
Lerda E........................................... P-110
Khiri H.............................................. O-12
Levi J. E.......................................... P-080
Kim S. S.......................................... P-012
Levy V..............................................P-020
Kiyingi H.......................................... P-072
Levy Y................................................. I-13
Kizito N........................................... P-061
Lim S. H.......................................... P-181
Knauth D.........................................P-126
López S........................................... P-063
Konan K. R...................................... P-156
Lopez-Huerta M.R............................... I-15
Kostrikis L. G.................................. P-028
Lovejoy C......................................... P-004
Kozal M.............................................. I-19
Luiz Neves W................................... P-031
Krempf M........................................P-090
Lukashov V...................................... P-112
Kumar A..........................................P-141
Luz Torres K..........................P-031, P-080
Kumar M......................................... P-013
Luzze C........................................... P-061
Kumarpillai G................................... P-013
Luzzi A............................................ P-070
Kurbatska V.................................... P-044
Kurth J........................................... P-024
M
Kutamba E...................................... P-057
M.Akinola S..................................... P-189
Macpherson P................................. P-085
L
Madani Ghahfarokhi S......................P-130
L. Rao S.......................................... P-013
Maga G............................................. O-16
La Porte C.......................................... I-09
Magalhães Coelho F......................... P-191
Labarga P.................... O-13, P-051, P-076
Magnano San Lio M......................... P-002
Labarrière B.................................... P-110
Magnier J. D..................................... O-10
Lacheheb A...................................... P-099
Maia M........................................... P-121
Lagane B......................................... P-163
Maida P........................................... P-042
Laisaar K. T..................................... P-142
Malheiro A................. P-031, P-080, P-190
Lambotte O........................................ I-26
Malhotra R......................................P-105
Lamsal S......................................... P-158
Mallon P............................................. I-31
Landay A.L..........................................I-28
Mancino P.............................P-062, P-064
Lavens D......................................... P-024
Mandelbrot L........................ P-113, P-164
Le Grand R...............................I-32, P-011
Maneshi H................. P-119, P-136, P-151
Le Tortorec A.................................. P-011
Lecollinet S..................................... P-186
Manfredi R..... P-033, P-034, P-036, P-040,
P-041, P-045, P-052, P-058,
P-060, P-067, P-068, P-071,
P-083, P-084, P-086, P-091,
P-102, P-128, P-159, P-171,
P-172, P-174, P-175, P-176,
P-178, P-179, P-180, P-192
Lee Y. L........................................... P-181
Mangeot-Mederle I.............................. I-32
Lefebvre G....................................... P-186
Mankad B. O-14, P-049, P-053, P-065, P-075
Legall C........................................... P-108
Marchetti I...................................... P-002
Lebcir R.......................................... P-157
Leblond A........................................ P-186
Lebre A........................................... P-074
53
AUTHORS INDEX
INDEX DES AUTEURS
Margolis D..........................................I-17
Morettini F...................................... P-070
Maricic A.........................................P-160
Morin G...........................................P-116
Marino N........................................ P-029
Morton M....................................... P-105
Marques N...................................... P-074
Moscatelli C.................................... P-002
Marques R...................................... P-039
Motta Passos I................................ P-190
Martin J.N......................................... I-28
Mousavi M...................................... P-130
Martín-Carbonero L...............P-051, P-076
Mpiima D.........................................P-061
Martinez E..........................................I-05
Mugerwa R..................................... P-035
Martinson J.A.................................... I-28
Mugisha K....................................... P-177
Masembe V..................................... P-152
Muhumuza S.............. P-043, P-057, P-077
Mauricio Carvalho Guedes R............. P-191
Mulenga J....................................... P-105
Mazeron M. C................................... O-10
Murdaca G........................................ O-06
Mazzotta F...................................... P-029
Muriaux D....................................... P-006
Mbabazi E....................................... P-043
Musso A............................................O-06
Mbayiha H. A...................................P-027
Mccadney S..................................... P-150
N
Mccune J.M....................................... I-28
Namusobya J...................................P-043
Mechakra S..................................... P-099
Nannyonga M.................................. P-072
Mechler C....................................... P-113
Narciso P.......................................... O-11
Medrano J................... O-13, P-051, P-076
Natal D........................................... P-183
Meijide H......................................... P-063
Neves L................................ P-066, P-188
Melendez L...................................... P-010
Nguyen T............................................ I-03
Meliço Silvestre A............................ P-074
Nicand E........................................... O-10
Melki M. T.................................O-05, O-07
Nicastri E.......................................... O-11
Mena Á........................................... P-063
Nihalani U........ O-14, P-049, P-053, P-065,
P-075
Menard A............................. P-059, P-092
Merino A......................................... P-105
Metadilogkul O................................ P-030
Metcalfe J......................................... O-01
Mgbere O........................................ P-120
Miro J.M............................................ I-25
Mishra A......................................... P-106
Moecklinghoff C................................. O-15
Moelling K....................................... P-095
Nikolopoulos G.................................P-129
Noel M............................................ P-152
Normand L...................................... P-116
Norris P.J...........................................I-28
Nunès J. A...................................... P-007
Nuvor S. V.......................................P-009
Nyatia R. J...................................... P-155
Moetter J........................................P-018
O
Mohammadi M. A............................ P-130
Obry-Roguet V....................... P-059, P-092
Monjok E......................................... P-120
Ocero A........................................... P-035
Montagna C.....................................P-042
Ochei U........................................... P-054
Montes M. L..................................... O-15
Odeke E...........................................P-155
Moradi G......................................... P-101
Oguntibeju O......................... P-138, P-144
Moreau M....................................... P-011
Olive D......................... O-04, P-007, P-008
Oliveira J......................................... P-074
54
Onnis A........................................... P-070
Pinilla J........................................... P-076
Onoh O............................................ P-054
Pittaluga A...................................... P-005
Onyenechere E................................. P-118
Plassart F............................. P-047, P-078
Oparah A......................................... P-054
Plata Paniagua S............................. P-166
Orisatoki R........................... P-138, P-144
Plaud M.......................................... P-010
Orlovsky V....................................... P-030
Poggi A................................... O-06, P-025
Otis J.............................................. P-116
Poizot-Martin I...................... P-059, P-092
Ouguerram K................................... P-090
Poli G................................................. I-12
Ouma J................................. P-043, P-077
Poonia B............................................O-08
Ouyahia A........................................ P-099
Porcu-Buisson G................................ O-12
Oyebola F. O.................................... P-094
Porto Dos Santos M........................ P-190
Posner J......................................... P-152
P
Pradier S.........................................P-186
Palmer S............................................ I-16
Prajapati G...... P-049, P-053, P-065, P-075
Panagiota M.................................... P-184
Prajapati S....... O-14, P-049, P-053, P-065,
P-075
Panoutsopoulos A............................ P-184
Pant S. B........................................ P-122
Pantaleo G...................................... P-021
Paolucci S......................................... O-16
Parodi A.......................................... P-025
Pasqualini C.....................................P-098
Patrick P........................................... O-04
Paula L. D....................................... P-190
Pauline F........................................... O-05
Pauza D.............................................O-08
Pedreira J....................................... P-063
Peelman F........................................P-024
Pellicanò G...................................... P-022
Pénaranda G......................................O-12
Perez Resende Oliveros M................ P-050
Perez-Olmeda M.................................. I-15
Petit N............................................ P-110
Petkovic N.......................................P-160
Peudepiece P................................... P-108
Philippe H.......................................... O-04
Picerno I..........................................P-022
Piedimonte G................................... P-022
Pigeon A.......................................... P-162
Pilecco F.......................................... P-126
Pilowsky D.......................................P-106
Pineiro C......................................... P-039
Prakash M........................................ O-15
Profy A. T........................................ P-017
Puliti A............................................ P-005
Puong K. Y.......................................P-182
Purohit H.O-14, P-049, P-053, P-065, P-075
Q
Quaresma Bomfim M. R................... P-191
Quintas E........................................ P-039
R
Radi M.............................................. O-16
Rafiee H.......................................... P-130
Rahsaz M........................................ P-088
Rai S............................................... P-124
Raimondo M.................................... P-098
Rais M............................................ P-099
Raiteri M.........................................P-005
Rapicetta M.................................... P-029
Rathod G........................................... O-14
Regine V.......................................... P-098
Rehman K........................................P-087
Reichenberg J.................................. P-160
Reis R.................................. P-066, P-188
Renda V........................................... P-042
Resende M...................................... P-191
55
AUTHORS INDEX
INDEX DES AUTEURS
Rezza G.............................................. I-02
Semage S........................................ P-117
Ribeiro De Castro Duarte A. M........ P-183
Semitala F............................ P-043, P-077
Ribeiro P......................................... P-188
Serrano J........................................ P-063
Ricas Rezende H.............................. P-183
Serrao R......................................... P-039
Richard M. E................................... P-116
Setti M............................................. O-06
Riedel D............................................ O-08
Severi P...........................................P-005
Rizzo B............................................ P-042
Shabbir N............................. P-134, P-148
Rodriguez E..................................... P-010
Shah A... O-14, P-049, P-053, P-065, P-075
Romeu R......................................... P-010
Shahbazi M........................... P-081, P-101
Roques P......................................... P-011
Shahrokhi M....................................P-169
Roshanfekr P................................... P-130
Shahrokhi N.................................... P-169
Routy J.-P........................................... I-18
Shankar P....................................... P-012
Rowland-Jones S..............................P-009
Sharapov M.......................................O-09
Rozera G........................................... O-11
Sharma A........................................ P-142
Rudevica Z.......................................P-044
Shatokhin A.....................................P-133
Rueda P...........................................P-163
Shen R............................................ P-023
S
S.Chandra P.................................... P-013
Sabbatani S....P-040, P-041, P-084, P-176,
P-178
Shevkani M...... O-14, P-049, P-053, P-065,
P-075
Sheyani M....................................... P-130
Silva Fraporti L..................... P-031, P-080
Sinclair E............................................ I-28
Sadeghzadeh V.................................P-093
Singh S. K....................................... P-135
Saez-Ciron A....................................... I-27
Singh U........................................... P-124
Saïdi H..................................... O-05, O-07
Sinha G........................................... P-146
Sajadi M............................................ O-08
Skolasky R...................................... P-010
Salari K........................................... P-020
Smith P. D....................................... P-023
Salfa M. C....................................... P-098
Soares J......................................... P-039
Samarakoon S................................. P-117
Soares R......................................... P-183
Sanchez C. A................ O-13, P-051, P-076
Sobhie Diaz R.................................. P-050
Sandoz A......................................... P-186
Sohail S...........................................P-069
Sanjurjo Saez M...............................P-166
Solas C.................................... I-11, P-059
Sanson Le Pors M. J......................... O-10
Songa J........................................... P-152
Santiago J....................................... P-111
Soriano V.............. I-23, O-13, P-051, P-076
Saraiva Da Cunha J......................... P-074
Soumelis V.......................................P-007
Sarmento A..................................... P-039
Souza Cunha M. D. G....................... P-190
Satie A. P........................................ P-011
Spataro P........................................ P-022
Satishchandra P.............................. P-013
Spigner C........................................ P-111
Sayana S......................................... P-048
Srikant S.........................................P-145
Schols D..........................................P-017
Srivastava J.................................... P-141
Schwartz-Cornil I............................. P-023
Ssempiira J..................................... P-043
Sekiranda P..................................... P-155
Staropoli I....................................... P-163
Sellier P............................................ O-10
Stojanovic M................................... P-160
56
Study Group M.................................. O-15
U
Su B................................................P-096
Ucciferri C............................ P-062, P-064
Subramanya S................................. P-012
Urbinatti P. R.................................. P-183
Suligoi B.......................................... P-098
Uusküla A........................................ P-142
Summa M........................................P-005
Uyttendaele I................................... P-024
Swenson D...................................... P-004
Uzma Q........................................... P-148
T
V
Tabatabaee M..................................P-088
Vameghi M...................................... P-130
Taffon S.......................................... P-029
Van Der Heyden J............................ P-024
Tamalet C........................................ P-059
Van Lint C......................................... O-04
Tang J............................................. P-105
Van Schouwbroeck B........................P-024
Tang J............................................. P-170
Vandercam B................................... P-055
Taponeco F.......................................P-002
Vásquez F........................................ P-080
Tarragô A............................. P-031, P-080
Vassiliki L........................................ P-184
Tasca G........................................... P-085
Vázquez P........................................ P-063
Tavernier J...................................... P-024
Vecchiet J............................. P-062, P-064
Tayyebi D......................................... P-088
Velásquez C..................................... P-046
Tejada R.......................................... P-046
Verdin E............................................ O-04
Terriou P........................................... O-12
Vermeire K...................................... P-017
Tesse S............................................. O-10
Viana Maia L. P..................... P-031, P-080
Theodoros M................................... P-184
Victoria F........................................ P-080
Thériault J....................................... P-116
Victoria M....................................... P-080
Thole C. K. F.................................... P-140
Vieillard V........................................... I-32
Timezouaght N................................ P-110
Vignale F............................... P-062, P-064
Tommasi C.........................................O-11
Vinai G............................................ P-110
Toni T..................................................I-21
Vipul V.............................................P-145
Touarhi T.................... P-047, P-078, P-162
Visalli G...........................................P-022
Touré P............................................P-156
Vispo E........................ O-13, P-051, P-076
Touré S........................................... P-156
Voudoukis E..................................... P-184
Towfic G.......................................... P-015
Traeder C........................................ P-082
Tran A............................................. P-186
Tran G. M. K......................... P-168, P-173
Traoré A. S......................................P-167
Trejbalova K.......................................O-04
Trottier G........................................ P-116
Trovato Lopez N...............................P-166
Tsiara C...........................................P-129
Tsimanis A....................................... P-044
Tudor D........................................... P-023
Turriziani O...................................... P-042
57
W
Wainberg M........................................I-21
Walle E. S. F....................................P-002
Wang X. R....................................... P-100
Warfield K....................................... P-004
Warren T......................................... P-004
Watt J.............................................. O-01
Wells J............................................ P-004
Westenhouse J.................................. O-01
Whittle H........................................ P-009
AUTHORS INDEX
INDEX DES AUTEURS
Willbold D....................................... P-018
Wilson E..........................................P-122
Wong K........................................... P-116
X
Xia Q.................................................O-01
Xing J............................................. P-103
Y
Yamasaki T...................................... P-183
Yang Z...............................................O-03
Ye C................................................ P-012
Yombi J. C....................................... P-055
Z
Zair Y.............................................. P-090
Zajeganovic J................................... P-160
Zare S.................................. P-119, P-151
Zhang K.......................................... P-103
Zhao J.................................... O-03, P-100
Zi Y. Y..............................................P-100
Zimba I............................................ P-002
Zocchi M. R............................ O-06, P-025
58
INDUSTRY SATELLITE
SYMPOSIA
SYMPOSIA SATELLITE
DE L’INDUSTRIE
Wednesday 24 March / Mercredi 24 mars
SHAPPING THE FUTURE OF CO-INFECTIONS
WITH NOVEL AGENTS / MODELER L’AVENIR
DES CO-INFECTIONS À L’AIDE DE NOUVEAUX
AGENTS
Wednesday 24 March - 13:00 - 14:00
(Callelongue Amphitheater) /
Mercredi 24 mars - 13:00 - 14:00
(Amphitéâtre Callelongue)
page 15
STEERING FOR NEW STRATEGIES / METTRE
LE CAP SUR DE NOUVELLES STRATÉGIES
Wednesday 24 March - 17:00 - 18:30
(Callelongue Amphitheater)
Mercredi 24 mars - 17:00 - 18:30
page 17
In French only / En français seulement
Thursday 25 March / Jeudi 25 mars
UNE DIVISION DE
SWITCHING FROM STABLE REGIMEN: WHICH
RISKS, WHICH BENEFITS ? / CHANGEMENT
DE TRAITEMENT ANTIRÉTROVIRAL CHEZ LES
PATIENTS EN SUCCÈS VIROLOGIQUE : QUELS
RISQUES, QUELS BÉNÉFICES ?
Thursday 25 March - 12:30 - 14:00
Jeudi 25 mars - 12:30 - 14:00
page 20
In English only / En anglais seulement
HIV, A CHRONIC DISEASE: WHAT PRIORITIES
TO MANAGE ? / LE VIH, UNE PATHOLOGIE
CHRONIQUE : QUELLES PRIORITÉS À PRENDRE
EN CHARGE ?
Thursday 25 March - 17:00 - 18:30
Jeudi 25 mars - 17:00 - 18:30
page 21
59
EXHIBITION MAP
PLAN DE L’EXPOSITION
The exhibition area is located at level 2, hall des pas perdus. /
L’exposition est siutée au niveau 2, hall des pas perdus.
OPENING HOURS / HORAIRES D’OUVERTURE
Wednesday 24 March / Mercredi 24 mars: 08:00 - 19:30
Thursday 25 March / Jeudi 25 mars: 07:30 - 18:30
Friday 26 March / Vendredi 26 mars: 07:30 - 17:00
COMPANIES/ SOCIÉTÉS :
Abbott France
Booth number/ stand : 10
Boehringer Ingelheim France
Booth Number/ stand : 20
Cellestis Gmbh
Booth number/ stand : 17
Gilead
Booth Number/ stand : 07:
ViiV Healthcare
Laboratoires Merck Sharp & Dhome
Roche
Schering Plough
Tibotec / Janssen Cilag
Wisepress
60
GOUDES ROOM / SALLE DES GOUDES
POSTERS / COMMUNICATIONS AFFICHÉES
COFFEE
BREAK
PAUSE
CAFÉ
AUDITORIUM
18
19
20
17
16
@
CYBER
SPACE
CYBER
ESPACE
10
08
07
01
06
PREVIEW ROOM
SALLE DE
PRÉPROJECTION
COFFEE
BREAK
PAUSE
CAFÉ
AMPHITHEATER
CALLELONGUE
AMPHITHÉÂTRE
CALLELONGUE
COFFEE
BREAK
PAUSE
CAFÉ
WELCOME DESK
ACCUEIL
CLOAKROOM
VESTIAIRE
ENTRANCE
ENTRÉE
6161
SPONSORS
PARTENAIRES
ABBOTT
Abbott, 120 years of technological and scientific innovations, especially regarding HIV/AIDS
• 1985:1st AIDS screening test
• 1996: launch of Norvir™
• 2001: launch of Kaletra® caps
• 2006: Kaletra® tablets 200/50 mg
• 2008: Kaletra® tablets 100/25 mg and launch of the blister pack
• 2009: launch of Kaletra® tablets 200/50 mg OAD for naive patients
Abbott, a strong humanitarian commitment
• for the people from the 154 developing countries
• for the children affected by HIV/AIDS
Abbott Found has been supporting more than 600 000 children and families since 7 years (Care
and Health Care Education programmes)
Abbott, 120 ans d’histoire jalonnée d’innovations technologiques et scientifiques, notamment
concernant le VIH/sida :
• 1985 :1er test du dépistage du Sida
• 1996 : lancement de Norvir™
• 2001 : lancement de Kaletra® capsule
• 2006 : mise à disposition de Kaletra® comprimé 200/50 mg
• 2008 : mise à disposition de Kaletra® comprimé 100/25 mg et lancement de Kaletra®
comprimé 200/50 mg en blister
• 2009 : lancement de Kaletra® comprimé 200/50 mg en OAD chez les patients naïfs
Abbott, un engagement humanitaire fort
• Pour les populations de 154 pays en voie de développement ou à revenus intermédiaires
• Pour les enfants atteints du VIH / Sida
Abbott et sa fondation Abbott Found soutiennent depuis 7 ans plus de 600 000 enfants
et familles par des programmes communautaires (apports de soins, programmes d’éducation et
services sociaux)
BOEHRINGER INGELHEIM
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies.
Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and
41,300 employees. Since it was founded in 1885, the independent, family-owned company has
been committed to researching, developing, manufacturing and marketing novel products of high
therapeutic value for human and veterinary medicine.
In 2008, Boehringer Ingelheim posted net sales of 11.6 billion euro while spending one fifth of
net sales in its largest business segment Prescription Medicines on research and development.
The Boehringer Ingelheim groupis present on HIV Market through two treatments:
- > Viramune ® (névirapine), a Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
-> Aptivus ® (tipranavir), a protease inhibitor launched in 2007.
The Boehringer Ingelheim group is also commited in the fight against HIV infection in developing
countries due to 3 actions:
-> VIRAMUNE Donation Programme for Prevention of Mother-To-Child-Transmission
-> Adjusted Pricing for chronic treatment (Member of the Accelerating Access Initiative (AAI))
-> Extended access to nevirapine
-> Health Care Supporting Activities
For more information please visit www.boehringer-ingelheim.fr
Le groupe pharmaceutique Boehringer Ingelheim, dont le siège se situe à Ingelheim en Allemagne,
figure parmi les 20 premières entreprises du médicament au monde. Le groupe compte 138
filiales dans 47 pays et près de 41 300 employés.
Notre entreprise indépendante à capitaux privés est engagée depuis 1885 dans la recherche
et le développement, la fabrication et la commercialisation de produits d’intérêt thérapeutique
majeur à usage humain et vétérinaire.
Les laboratoires Boehringer Ingelheim sont présents sur le marché des traitements des infections à
VIH à travers deux traitements :
-> Viramune® (névirapine), un inhibiteur non nucléosidique de la transcriptase inverse, mis sur le
62
marché en 1998 et bénéficiant d’une expérience de 12 ans.
-> Aptivus® (tipranavir), une anti-protéase lancée en 2007.
Les laboratoires Boehringer Ingelheim sont également engagés dans la lutte contre l’infection à
VIH dans les pays en voie de développement, grâce à des actions orientées selon 3 axes:
-> Programme de dons,
-> Proposition d’une échelle de prix adapté en fonction du PIB des différents pays concernés
-> Cession de licences aux différents fabricants de génériques agréés par l’OMS
Pour plus d’information, consulter notre site Internet : www.boehringer-ingelheim.fr
CELLESTIS
Cellestis is a listed Australian biotechnology company that is a leader in the detection and control
of tuberculosis, with the development of its breakthrough blood test QuantiFERON®-TB Gold InTube (QFT™). Cellestis is focused on developing diagnostics tests that measure immune function
for diseases with an unmet medical need.
Cellestis Limited est une entreprise de biotechnologie australienne fondée en 2000 à Melbourne
(Australie). Elle développe et commercialise le test « QuantiFERON-TB Gold In-Tube® (QFT ™) »,
un test sanguin innovant permettant le dépistage de l’infection tuberculeuse et de la tuberculose
maladie. En utilisant QuantiFeron® technology, une méthode brevetée, Cellestis développe des
tests diagnostics permettant de mesurer la fonction immunitaire en méthode ELISA.
GILEAD
Combattre les maladies engageant le pronostic vital
Chez Gilead, nous appliquons le meilleur de la recherche biopharmaceutique pour créer des
traitements innovants dans la lutte contre le VIH/SIDA, les maladies hépatiques et les atteintes
respiratoires et cardiovasculaires sévères.
Surpasser les standards thérapeutiques actuels
Nous recherchons constamment de nouvelles molécules plus puissantes, avec de meilleurs profils
de résistances, des indices de tolérance plus favorables et plus simples.
Avec chaque percée thérapeutique, nous tâchons de faire avancer significativement la prise en
charge des patients et d’améliorer la vie.
JANSSEN CILAG-TIBOTEC
Tibotec is changing people’s lives and improving public health by fighting infectious diseases
worldwide. We are achieving this by delivering innovative therapeutic and diagnostic solutions that
provide significant benefits to patients. Tibotec recognizes its responsibility to collaborate in the
international response to HIV/AIDS, a challenge which cannot be separated from the fight for
gender equality and poverty reduction.
Tibotec R&D is dedicated to the discovery and development of innovative new drugs for HIV/
AIDS and other infectious diseases of high unmet medical need. Tibotec was established in 1994
by Rudi Pauwels as a drug discovery laboratory. In 1995, Virco was established as a spin-off to
improve the management of HIV/AIDS with innovative, new molecular diagnostic tools for HIV
resistance testing that would better inform the treatment decisions made by physicians. In April
2002 Tibotec and Virco were acquired by Johnson & Johnson. Under the leadership of Paul
Stoffels, Tibotec evolved to a fully integrated pharmaceutical company focusing on the discovery
and the development of new drugs for Infectious Diseases.
http://www.tibotec.com/
Janssen-Cilag axe son développement dans des domaines thérapeutiques hautement spécialisés
qui répondent à des enjeux majeurs en santé : la psychiatrie, l’infectiologie (antibiothérapie et
virologie), la cancérologie (hématologie), la dermatologie et la douleur.
Engagé dans l’innovation thérapeutique, Janssen-Cilag va plus loin : le laboratoire vise la prise
en charge globale des maladies par un travail pluridisciplinaire. Pour assurer celle-ci, il crée,
développe et supporte des actions, des services et des programmes.
A l’écoute de l’ensemble des acteurs de santé : médecins, personnel soignant, patients, société
civile..., nos équipes œuvrent pour répondre à leurs attentes en visant la santé de tous. Innovation,
écoute et partage des connaissances qui constituent les valeurs clés de Janssen-Cilag
63
SPONSORS
PARTENAIRES
LABORATOIRES MERCK SHARP & DOHME-CHIBRET
Subsidiary of Merck and Co. Inc., Laboratory MSD-Chibret participates in the improvement of the
health in the world. With its drugs, vaccines, biological therapies, animal and consumer health
products, the Group MSD proposes innovative solutions in more than 140 countries worldwide.
Its commitment in favour of the access to healthcare is also made through wide programs of
donation and provision of drugs for those who more need it.
MSD, to Live better.
For more information, go on www.merck.com or www.msd-france.com
Filiale de Merck & Co. Inc., les Laboratoires MSD-Chibret participent à l’amélioration de la santé
dans le monde. Avec ses médicaments, vaccins, thérapies biologiques, produits de santé animale
et grand public, le Groupe MSD propose des solutions innovantes dans plus de 140 pays à
travers le monde. Son engagement en faveur de l’accès aux soins se fait également à travers de
larges programmes de donation et de mise à disposition de médicaments pour ceux qui en ont
le plus besoin.
MSD, Vivre mieux.
Pour plus d’informations, rendez-vous sur www.merck.com ou www.msd-france.com
ROCHE / ROCHE
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with
combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech
company with truly differentiated medicines in oncology, virology, inflammation, metabolism and
CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and
a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing
medicines and diagnostic tools that enable tangible improvements in the health, quality of life and
survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost
10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech,
United States, is a wholly owned member of the Roche Group. Roche has a majority stake in
Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche, dont le siège est à Bâle, Suisse, figure parmi les leaders de l’industrie pharmaceutique
et diagnostique axée sur la recherche. Numéro un mondial de la biotechnologie, Roche produit
des médicaments cliniquement différenciés pour le traitement du cancer, des maladies virales
et inflammatoires ainsi que des maladies du métabolisme et du système nerveux central. Roche
est aussi le leader mondial du diagnostic in vitro ainsi que du diagnostic histologique du cancer,
et une entreprise pionnière dans la gestion du diabète. Sa stratégie des soins personnalisés vise
à mettre à disposition des médicaments et des outils diagnostiques permettant d’améliorer de
façon tangible la santé ainsi que la qualité et la durée de vie des patients. En 2009, Roche, qui
comptait plus de 80 000 employés dans le monde, a consacré à la R&D près de 10 milliards
de francs. Son chiffre d’affaires s’est élevé à 49,1 milliards de francs. Genentech, Etats-Unis,
appartient entièrement au groupe Roche, qui détient en outre une participation majoritaire au
capital de Chugai Pharmaceutical, Japon. Pour de plus amples informations, consulter le site
internet du groupe à l’adresse www.roche.com.
Tous les noms de marque mentionnés sont protégés par la loi.
SCHERING PLOUGH
As a part of Merck & Co. Inc, Schering-Plough is working to help the world be well. Through
our medicines, vaccines, biologic therapies, and consumer and animal products, we work with
customers and operate in more than 140 countries to deliver innovative health solutions. We also
demonstrate our commitment to increasing access to health care through far-reaching programs
that donate and deliver our products to the people who need them.
Merck & Co. Be Well.
For more information, visit www.merck.com
Filiale de Merck & Co. Inc., Schering-Plough participe à l’amélioration de la santé dans le monde.
Avec nos médicaments, vaccins, thérapies biologiques, produits de santé animale et grand public,
nous proposons des solutions innovantes dans plus de 140 pays à travers le monde. Notre
engagement en faveur de l’accès aux soins se fait également à travers de larges programmes de
donation et de mise à disposition de médicaments pour ceux qui en ont le plus besoin.
Merck & Co. Vivre mieux.
Pour plus d’informations, rendez-vous sur www.merck.com
64
ViiV HEALTHCARE SAS
ViiV Healthcare is a new specialist HIV company established by Glaxosmithkline (GSK) and Pfizer,
committed to delivering advances in treatment and improving access to medicines for people
living with HIV/AIDS in Europe and worldwide.
ViiV Healthcare was launched the 3rd of November 2009.
With 10 medicines currently available and a pipeline of seven innovative and targeted medicines,
including five compounds in phase II, ViiV Healthcare has 17 molecules in its portofolio to develop
as potential new HIV treatments.
ViiV Healthcare SAS was launched the 1st of February in France.
Its team will manage a large group of medicines, stemming from the GSK and Pfizer portofolios :
Celsentri® maraviroc, Kivexa® abacavir-lamivudine, Telzir® fosamprenavir, Combivir® lamivudinezidovudine, Trizivir® abacavir-lamivudine-zidovudine, Ziagen® abacavir, Epivir® lamivudine,
Retrovir® zidovudine, Agenerase® amprenavir et Rescriptor® delavirdine.
Medical information: 01 39 17 69 69. [email protected].
ViiV Healthcare est née de la volonté des laboratoires GSK et Pfizer de marquer fortement leur
engagement dans la lutte contre le VIH, en créant une société dédiée à la recherche dans ce
domaine et au traitement de cette maladie, centrée sur les besoins des patients et engagée dans
l’innovation. La société a été créée au niveau mondial en novembre 2009.
Avec 10 médicaments déjà commercialisés et 7 molécules ciblées et innovantes en développement,
donc 5 en phase 2, ViiV Healthcare détient un potentiel unique pour le traitement et les stratégies
thérapeutiques contre le VIH dans les années à venir..
La filiale française, ViiV Healthcare SAS, a été lancée le 1er février 2010.
Ses équipes sont désormais en charge de l’ensemble des antirétroviraux qui appartenaient aux
portefeuilles de GSK et de Pfizer : Celsentri® maraviroc, Kivexa® abacavir-lamivudine, Telzir®
fosamprenavir, Combivir® lamivudine-zidovudine, Trizivir® abacavir-lamivudine-zidovudine, Ziagen®
abacavir, Epivir® lamivudine, Retrovir® zidovudine, Agenerase® amprenavir et Rescriptor®
delavirdine (produit en ATU nominative).
Information médicale : 01 39 17 69 69 ou par mail : [email protected].
WISEPRESS
Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and
journals relevant to the themes of the meeting
Wisepress Medical Bookshop
The Old Lamp Works
25 High Path
Merton Abbey
London SW19 2JL UK
Phone: +44 20 8715 1812
Fax:
+44 20 8715 1722
[email protected]
www.wisepress.com
65
NOTES
66
67
SPONSORS
PARTENAIRES
The Organising Committee would like to thank the following companies for their
generous support of the 16 ISHEID.
Le Comité d’Organisation souhaite remercier les sociétés suivantes de leur généreux
soutien pour la 16ème édition de l’ISHEID.
SILVER SPONSORS / PARTENAIRES ARGENT
ABBOTT France
BRISTOL-MYERS SQUIBB
LABORATOIRES MERCK SHARP
& DOHME-CHIBRET
GILEAD
SCHERING PLOUGH
UNE DIVISION DE
TIBOTEC / JANSSEN CILAG
BRONZE SPONSORS / PARTENAIRES BRONZE
BOEHRINGER INGELHEIM
VIIVHEALTHCARE
SPONSORS / PARTENAIRES
© colloquium 03/10
CELLESTIS
ROCHE
WISEPRESS

CONTENTS - BioMed Central

Transcription

Documents pareils

Cover Aug 2004 New

PSM Toolbox - Guidelines for intensified tuberculosis case

EMPLOYMENT OPPORTUNITY : HIV EDUCATOR

en analyses biomédicales, IAL, CHUV, Lausanne

Symposium L`actualité de la recherche en droit franco

Ça dépend du contexte

PROFIDYS - Dysplasie fibreuse des os

La grande rafle du Vel` d`Hiv

Canadian Society for History and Philosophy of Mathematics